Apparatus and method of placement of a graft or graft system

Information

  • Patent Grant
  • 10245166
  • Patent Number
    10,245,166
  • Date Filed
    Wednesday, May 31, 2017
    7 years ago
  • Date Issued
    Tuesday, April 2, 2019
    5 years ago
Abstract
An endoluminal prosthesis system deployable in a region of a patient's vasculature having one or more branch vessels, having a main graft body having a first opening in a wall portion of the main graft body and a pre-loaded guidewire positioned inside the main graft body and advanced through the first opening. One or more branch grafts can be attached to the main graft body to cover one or more openings in the main graft body.
Description
BACKGROUND

Technical Field


The present invention relates to endoluminal vascular prostheses and methods of placing such prostheses, and, in one application, to endoluminal vascular prostheses for use in the treatment of vessels with branches.


Description of the Related Art


An abdominal aortic aneurysm is a sac caused by an abnormal dilation of the wall of the aorta, a major artery of the body, as it passes through the abdomen. The abdomen is that portion of the body which lies between the thorax and the pelvis. It contains a cavity, known as the abdominal cavity, separated by the diaphragm from the thoracic cavity and lined with a serous membrane, the peritoneum. The aorta is the main trunk, or artery, from which the systemic arterial system proceeds. It arises from the left ventricle of the heart, passes upward, bends over and passes down through the thorax and through the abdomen to about the level of the fourth lumbar vertebra, where it divides into the two common iliac arteries.


The aneurysm usually arises in the infrarenal portion of the diseased aorta, for example, below the kidneys. When left untreated, the aneurysm may eventually cause rupture of the sac with ensuing fatal hemorrhaging in a very short time. High mortality associated with the rupture led initially to transabdominal surgical repair of abdominal aortic aneurysms. Surgery involving the abdominal wall, however, is a major undertaking with associated high risks. There is considerable mortality and morbidity associated with this magnitude of surgical intervention, which in essence involves replacing the diseased and aneurysmal segment of blood vessel with a prosthetic device which typically is a synthetic tube, or graft, usually fabricated of polyester, urethane, Dacron®, Teflon®, or other suitable material.


To perform the surgical procedure requires exposure of the aorta through an abdominal incision which can extend from the rib cage to the pubis. The aorta must typically be closed both above and below the aneurysm, so that the aneurysm can then be opened and the thrombus, or blood clot, and arteriosclerotic debris removed. Small arterial branches from the back wall of the aorta are tied off. The Dacron® tube, or graft, of approximately the same size of the normal aorta is sutured in place, thereby replacing the aneurysm. Blood flow is then reestablished through the graft. It is necessary to move the intestines in order to get to the back wall of the abdomen prior to clamping off the aorta.


If the surgery is performed prior to rupturing of the abdominal aortic aneurysm, the survival rate of treated patients is markedly higher than if the surgery is performed after the aneurysm ruptures, although the mortality rate is still quite high. If the surgery is performed prior to the aneurysm rupturing, the mortality rate is typically slightly less than 10%. Conventional surgery performed after the rupture of the aneurysm is significantly higher, one study reporting a mortality rate of 66.5%. Although abdominal aortic aneurysms can be detected from routine examinations, the patient does not experience any pain from the condition. Thus, if the patient is not receiving routine examinations, it is possible that the aneurysm will progress to the rupture stage, wherein the mortality rates are significantly higher.


Disadvantages associated with the conventional, prior art surgery, in addition to the high mortality rate include the extended recovery period associated with such surgery; difficulties in suturing the graft, or tube, to the aorta; the loss of the existing aorta wall and thrombosis to support and reinforce the graft; the unsuitability of the surgery for many patients having abdominal aortic aneurysms; and the problems associated with performing the surgery on an emergency basis after the aneurysm has ruptured. A patient can expect to spend from one to two weeks in the hospital after the surgery, a major portion of which is spent in the intensive care unit, and a convalescence period at home from two to three months, particularly if the patient has other illnesses such as heart, lung, liver, and/or kidney disease, in which case the hospital stay is also lengthened. Since the graft must typically be secured, or sutured, to the remaining portion of the aorta, it is many times difficult to perform the suturing step because the thrombosis present on the remaining portion of the aorta, and that remaining portion of the aorta wall may many times be friable, or easily crumbled.


Since many patients having abdominal aortic aneurysms have other chronic illnesses, such as heart, lung, liver, and/or kidney disease, coupled with the fact that many of these patients are older, the average age being approximately 67 years old, these patients are not ideal candidates for such major surgery.


More recently, a significantly less invasive clinical approach to aneurysm repair, known as endovascular grafting, has been developed. Parodi, et al. provide one of the first clinical descriptions of this therapy. Parodi, J. C., et al., “Transfemoral Intraluminal Graft Implantation for Abdominal Aortic Aneurysms,” 5 Annals of Vascular Surgery 491 (1991). Endovascular grafting involves the transluminal placement of a prosthetic arterial graft in the endoluminal position (within the lumen of the artery). By this method, the graft is attached to the internal surface of an arterial wall by means of attachment devices (expandable stents), typically one above the aneurysm and a second stent below the aneurysm.


Stents can permit fixation of a graft to the internal surface of an arterial wall without sewing or an open surgical procedure. Expansion of radially expandable stents is conventionally accomplished by dilating a balloon at the distal end of a balloon catheter. In U.S. Pat. No. 4,776,337, for example, Palmaz describes a balloon-expandable stent for endovascular treatments. Also known are self-expanding stents, such as described in U.S. Pat. No. 4,655,771 to Wallsten.


In certain conditions, the diseased region of the blood vessels extends across branch vessels. The blood flow into these branch vessels is critical for the perfusion of the peripheral regions of the body and vital organs. Many arteries branch off the aorta. For example, the carotid arteries supply blood into the brain, the renal arteries supply blood into the kidneys, the superior mesenteric artery (“SMA”) supplies the pancreas, and hypogastric arteries to the reproductive organs, and the subclavian arteries supply blood to the arms. When the aorta is diseased, the branch vessels may also be affected. Thoracic aortic aneurysms may involve the subclavian and carotid arteries, abdominal aneurysms may involve the SMA, renal and hypogastric arteries. Aortic dissections may involve all branch vessels mentioned above.


There is a need to place endoluminal prostheses in the aorta without obstructing critical branch vessels. The embodiments of the endoluminal prostheses disclosed herein provide a solution to the problems described above.


SUMMARY OF SOME EXEMPLIFYING EMBODIMENTS

Some embodiments of the endoluminal prosthesis disclosed herein pertain to the design and method of placement of a branch graft system for endovascular treatment of diseased blood vessels. The branch graft system can comprise a tubular expandable main body and at least one branch graft. The branch graft is made from an expandable material, which can be ePTFE. In some embodiments, the diameter of the branch graft can be sufficiently small to be manipulated into the desired vascular position by moving the branch graft over a guidewire. The branch graft can be expanded to the diameter of the branch vessel by mechanical means, which can be a dilation balloon. In another embodiment of an endoluminal prosthesis, the main body of the branch graft system can have one large opening in the wall of the graft for the treatment of a second branch vessel. A second branch graft system can be placed inside of the first branch graft system, wherein the branch graft of the second branch graft system passed through the opening of the first branch graft system and the large opening of the second branch graft system overlaps with the branch graft of the first branch graft system.


In some embodiments, an endoluminal prosthesis system is disclosed that can comprise a first endoluminal prosthesis comprising a first main graft body having at least a first and a second opening therein and a second endoluminal prosthesis comprising a second main graft body having at least a first and a second opening therein. The first opening in the first main graft body can be smaller than the second opening in the first main graft body, and the first opening in the second main graft body can be smaller than the second opening in the second main graft body. Further, the second main graft body can be configured to be expandable substantially within the first main graft body such that the second opening of the second main graft body does not cover any portion of the first opening in the first main graft body, and such that the second opening of the first main graft body does not cover any portion of the first opening in the second main graft body. In some embodiments, when the second main graft body has been expanded within the first main graft body, the resulting endoluminal prosthesis system can have two small openings therein that are each approximately equivalent in diameter to the first opening in each of the first and second main graft bodies.


In some embodiments, a method of deploying a branch graft system in a portion of a patient's blood vessel having at least a first and a second branch blood vessel is described. In some embodiments, the method can comprise positioning a first main graft body having at least a first and a second opening therein in the patient's blood vessel so that the first opening can be substantially aligned with the first branch blood vessel and so that the second opening can be sufficiently aligned with the second branch blood vessel so that the first main graft body does not substantially cover either the first or second branch blood vessel. The method can further comprise positioning at least a portion of a second main graft body having at least a first and a second opening therein within the inside of the first main graft body so that the first opening of the second main graft body can be substantially aligned with the second branch blood vessel and so that the second opening of the second main graft body can be sufficiently aligned with the first branch blood vessel so that the second main graft body does not substantially cover either the first or second branch blood vessel. The method can further comprise expanding the first and second main graft bodies against the patient's blood vessel to create a multi-layer graft system having two openings through the wall thereof that are substantially aligned with the first and second blood vessels and have a diameter substantially equal to the first opening of each of the first and second main graft bodies, and supporting the first and second main graft bodies against the patient's blood vessel. In some embodiments the second opening in each of the first and second main graft bodies can be substantially larger than the first opening in each of the first and second main graft bodies.


In some embodiments, an endoluminal prosthesis is disclosed that can comprise an expandable main graft portion having an axial opening therethrough and at least a first branch opening therein and an expandable branch graft portion having a proximal end portion, a distal end portion, and an axial opening therethrough. In some embodiments, the branch graft portion can be supported by the main graft portion and the branch graft portion can be supported by the main graft portion so that the proximal end portion of the branch graft portion can be positioned around a periphery of the first branch opening in the main graft, and such that the axial opening through the branch graft portion can be in communication with the first branch opening formed in the main graft portion. In some embodiments, at least the distal end portion of the branch graft portion can be in a first, unexpanded state. In other words, in some embodiments, before the branch graft has been deployed in the desired vascular location, the distal end portion of the branch graft portion can have a diameter that is less than the diameter of the proximal end portion of the branch graft portion.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A is a perspective view of an embodiment of an endoluminal prosthesis.



FIG. 1B is a perspective view of the main body graft of the embodiment of the endoluminal prosthesis illustrated in FIG. 1A.



FIG. 1C is a perspective view of the partially expanded branch graft of the embodiment of the endoluminal prosthesis illustrated in FIG. 1A.



FIG. 1D is a perspective view of the branch graft illustrated in FIG. 1B before the branch graft 14 has been partially expanded.



FIG. 1E is a partial section view of the branch graft illustrated in FIG. 1D, wherein a portion of the branch graft has been partially expanded with the use of the balloon expander.



FIG. 2 is a partial section view of a portion of the embodiment of the endoluminal prosthesis illustrated in FIG. 1A, after the branch graft portion of the endoluminal prosthesis has been positioned within a branch artery.



FIG. 3 is a partial section view of a portion of the embodiment of the endoluminal prosthesis illustrated in FIG. 1A, showing a balloon expandable stent being positioned within the partially expanded branch graft of the endoluminal prosthesis.



FIG. 4 is a partial section view of a portion of the embodiment of the endoluminal prosthesis illustrated in FIG. 1A, showing a balloon expandable stent being expanded within the branch graft of the endoluminal prosthesis.



FIG. 5 is a partial section view of a portion of the embodiment of the endoluminal prosthesis illustrated in FIG. 1A, showing an expanded stent positioned within a branch graft of the endoluminal prosthesis.



FIG. 6 is a graphical illustration of the location of the two renal arteries with respect to the superior mesenteric artery (“SMA”) in 50 patients undergoing an abdominal aortic aneurysm (“AAA”) procedure.



FIGS. 7A and 7B are a front view and a section view, respectively, of another embodiment of an endoluminal prosthesis.



FIGS. 8A, 8B, and 8C are a perspective view, top view, and section view, respectively, of yet another embodiment of an endoluminal prosthesis.



FIGS. 9A and 9B are a perspective view and a side view, respectively, of an embodiment of a fenestrated endoluminal prosthesis.



FIGS. 10A and 10B are a perspective view and a side view, respectively, of another embodiment of a fenestrated endoluminal prosthesis.



FIGS. 11A and 11B are a perspective view and a side view, respectively, of another embodiment of a fenestrated endoluminal prosthesis.



FIG. 12 is a partial section view of the endoluminal prosthesis illustrated in FIGS. 10A, 10B positioned within an embodiment of a delivery catheter.



FIG. 13 is a side view of the embodiment of the endoluminal prosthesis illustrated in FIGS. 10A, 10B before the endoluminal prosthesis is placed in a delivery catheter.



FIG. 14 is a partial section view of a patient's vasculature illustrating guidewires inserted through the abdominal aortic and into the renal arteries.



FIG. 15 is a perspective view of the embodiment of the endoluminal prosthesis illustrated in FIGS. 10A, 10B in the deployed or expanded state.



FIG. 16 is a partial section view of a patient's vasculature illustrating the endoluminal prosthesis illustrated in FIGS. 10A, 10B deployed in the desired position within the patient's vasculature, after the components of the delivery system except for the guidewires have been retracted from the patient's vasculature.



FIG. 17 is a partial section view of a patient's vasculature illustrating the endoluminal prosthesis illustrated in FIGS. 10A, 10B deployed in the desired position within the patient's vasculature, after all of the components of the delivery system have been retracted from the patient's vasculature.



FIG. 18 is a partial section view of a patient's vasculature illustrating the endoluminal prosthesis illustrated in FIGS. 11A, 11B also deployed in the desired position within the patient's vasculature, after the components of the delivery system except for the guidewires have been retracted from the patient's vasculature.



FIG. 19 is a partial section view of a patient's vasculature illustrating both endoluminal prostheses positioned in the desired position within the patient's vasculature, after the components of the delivery system have been retracted from the patient's vasculature.



FIG. 20 is a perspective view of another embodiment of an endoluminal prosthesis with a scalloped end portion.



FIG. 21 is a perspective view of another embodiment of an endoluminal prosthesis with a large opening open to the proximal end of the graft.



FIG. 22 is a partial section view of a patient's vasculature illustrating two of the endoluminal prostheses illustrated in FIG. 21 deployed in the desired position within the patient's vasculature, after the components of the delivery system except for the hollow guidewires have been retracted from the patient's vasculature.



FIGS. 23 and 24 are partial section views of a patient's vasculature illustrating two of the endoluminal prostheses illustrated in FIG. 21 deployed in the desired position within the patient's vasculature, further illustrating a branch graft deployment catheter being guided into the right renal artery over a guidewire.



FIG. 25 is a partial section view of a patient's vasculature illustrating an embodiment of a stent being deployed in the branch graft positioned in a patient's right renal artery.



FIG. 26 is a partial section view of a patient's vasculature illustrating an embodiment of a stent after it has been deployed in the branch graft positioned in a patient's right renal artery.



FIG. 27 is a partial section view of a patient's vasculature illustrating an embodiment of a stent after it has been deployed in the branch graft positioned in a patient's right renal artery, further illustrating the delivery catheter being removed from the patient's vasculature.





DETAILED DESCRIPTION OF SOME EXEMPLIFYING EMBODIMENTS

The following detailed description is now directed to certain specific embodiments of the disclosure. In this description, reference is made to the drawings wherein like parts are designated with like numerals throughout the description and the drawings.


Certain embodiments described herein are directed to systems, methods, and apparatuses to treat lesions, aneurysms, or other defects in the aorta, including, but not limited to, the thoracic, ascending, and abdominal aorta, to name a few. However, the systems, methods, and apparatuses may have application to other vessels or areas of the body, or to other fields, and such additional applications are intended to form a part of this disclosure. For example, it will be appreciated that the systems, methods, and apparatuses may have application to the treatment of blood vessels in animals. In short, the embodiments and/or aspects of the endoluminal prosthesis systems, methods, and apparatuses described herein can be applied to other parts of the body or may have other applications apart from the treatment of the thoracic, ascending, and abdominal aorta. And, while specific embodiments may be described herein with regard to particular portions of the aorta, it is to be understood that the embodiments described can be adapted for use in other portions of the aorta or other portions of the body and are not limited to the aortic portions described.



FIG. 1A is a perspective view of an embodiment of an endoluminal prosthesis 10 (also sometimes referred to herein as a branch graft system) having a main body graft 12 and at least one branch graft 14. The branch graft 14 is shown in a partially expanded state. In some configurations, the main body graft 12 can be positioned in the abdominal aorta, which the branch graft or grafts 14 can be positioned within the left or right renal artery. In some configurations, the branch graft or grafts 14 can be positioned within any one or combination of the following: left renal artery, right renal artery, second lumbar, testicular, inferior mesenteric, middle sacral, or other vessels branching from the aorta. Thus, in some embodiments, the endoluminal prosthesis 10 can comprise any number of branch grafts 14 that are required for the specific application, including, but not limited to, two, three, or more branch grafts 14.


Because the branch graft or grafts 14 can be configured to conform to a wide range of vessels and a wide range of positions, the branch graft or grafts 14 can be of any suitable size, shape, or configuration, and can be attached to the main body graft 12 in any of a wide variety of locations. Therefore, some embodiments of the endoluminal prosthesis 10 can comprise only one branch graft 14. However, in some embodiments, the endoluminal prosthesis 10 can comprise two or more branch grafts 14, or any suitable number depending on the application.



FIG. 1B is a perspective view of the main body graft 12 of the embodiment of the endoluminal prosthesis 10 illustrated in FIG. 1A. FIG. 1C is a perspective view of the partially expanded branch graft 14 of the embodiment of the endoluminal prosthesis 10 illustrated in FIG. 1A. FIG. 1C illustrates the branch graft 14 before it has been assembled with the main body graft 12 to form the embodiment of the endoluminal prosthesis 10 illustrated in FIG. 1A. FIG. 1D is a perspective view of the branch graft 14 illustrated in FIG. 1B before the branch graft 14 has been partially expanded. FIG. 1E is a partial section view of the branch graft illustrated in FIG. 1D, wherein a portion of the branch graft 14 has been partially expanded with the use of the balloon expander 16.


With reference to FIGS. 1A-1E, one of many suitable methods for fabricating some embodiments of the endoluminal prosthesis 10 will be described. As will be described, the branch graft 14 in the pre-expanded state as shown in FIG. 1D can be partially expanded by the balloon expander 16 to form the partially expanded branch graft 14 shown in FIGS. 1A, 1C. In some embodiments, only the proximal end portion 14a of the branch graft 14 (i.e., the end of the branch graft 14 closest to opening 14b) can preferably be expanded by the balloon expander 16. To expand the branch graft 14, the balloon expander 16 can be partially inserted into the proximal end portion 14a of the pre-expanded branch graft 14 (shown in FIG. 1D) and inflated until the proximal end portion 14a of the branch graft 14 reaches the desired or suitable size. While the expansion being of the branch graft 14 can be performed with a balloon expander 16, as is illustrated in FIG. 1E, any suitable method of expanding the branch graft 14 can be employed, including but without limitation other forms of mechanical expanders. Thus, FIG. 1E illustrates only one of several suitable methods for partially expanding the pre-expanded branch graft 14 illustrated in FIG. 1D to form the partially expanded branch graft 14 illustrated in FIG. 1A, 1C.


In some arrangements, the proximal end portion 14a of the branch graft 14 can be expanded to approximately match or conform to the expected diameter of the branch vessel and/or the diameter of the opening 12a. Thus, the branch graft 14 can be configured so as to be expandable over a wide range of sizes and cross-sectional shapes, depending on the size or shape of the branch vessel that the branch graft 14 is intended to be supported by. After removing the balloon expander 16, the proximal portion of the partially expanded branch graft 14 can be trimmed to conform to the opening 12a formed in the main body graft 12. The opening 12a can be sized and positioned to conform to the desired size location of the partially expanded branch graft 14. Thereafter, as mentioned, the branch graft 14 can be attached to the main body graft 12 using adhesive, sutures, or any other suitable attachment method, to form the endoluminal prosthesis 10 illustrated in FIG. 1A. Any portion of the endoluminal prosthesis 10, including the main body graft 12 and/or the branch graft 14, or any other endoluminal prosthesis disclosed herein can be formed from PTFE, ePTFE, polyester, urethane, Dacron, Dacron®, Teflon®, or any other distensible polymeric material or other suitable material.


In some embodiments, the sutures used to attach the branch graft 14 (or any other branch graft disclosed herein) to the main body 12 (or any other main body or graft portion disclosed herein) can be made from a radiopaque (“RO”) material so that the location of the branch graft can be perceived in an x-ray or other radiation transmission during deployment. In some embodiments, the sutures can be made from platinum, gold, barium sulfate, or any other suitable RO material. Alternatively, RO markers can be sewn to or otherwise attached to the main body of the endoluminal prosthesis at any suitable position, such as but not limited to adjacent to or on the branch graft or near the end portions of the main body, again to aid in visualization of the endoluminal prosthesis during deployment.


In some embodiments, the diameter of the pre-expanded branch graft 14 (shown in FIG. 1D) can be from approximately 1 mm or less to approximately 3 mm or more. However, the pre-expanded diameter of the pre-expanded branch graft 14 (as illustrated in FIG. 1D) can be any suitable cross-sectional size or shape depending on the size and shape of the target artery or blood vessel. Additionally, in some embodiments, the shape of the pre-expanded branch graft 14 can be cylindrical. However, the shape of the pre-expanded branch graft 14 is not so limited. The pre-expanded branch graft 14 can define a curved, angled, tapered or other suitable shape.


In some embodiments, the branch graft 14 can be integrally formed with the main body graft 12. In some embodiments, the branch graft 14 can be attached to the main body graft 12 using sutures, adhesive, or any other suitable attachment material or method. The junction between the branch graft or grafts 14 and the main body graft 12 can be sealed so as to substantially inhibit or prevent blood from leaking through the junction and flowing between the main body graft 12 and the aorta or other blood vessel that the main body graft 12 is positioned within. In some embodiments, the junction between the branch graft or grafts 14 and the main body graft 12 can be sealed so as to inhibit or prevent at least the majority of the blood flowing therethrough from leaking through the junction and flowing between the main body graft 12 and the aorta or other blood vessel that the main body graft 12 is positioned within. In this configuration, the endoluminal prosthesis 10 can be less susceptible to leakage between the main body graft 12 and the aorta or blood vessel at the blood vessel branch point as compared to conventional fenestrated graft systems.


In some embodiments, the main body graft 12 or the branch graft 14 of the endoluminal prosthesis 10 can be similar in size, material, or other details to other suitable expandable bifurcated or non-bifurcated endoluminal prostheses presently known or later developed in the art, or can be of any size, material, or other details of any other prosthesis presently known or later developed in the art. For example, without limitation, in some embodiments, the main body graft 12 or the branch graft 14 can comprise any of the materials, features, or other aspects of the embodiments of the polymeric sleeves or the tubular wire supports disclosed in U.S. Pat. No. 6,077,296 (titled ENDOLUMINAL VASCULAR PROSTHESIS and filed on Mar. 4, 1998), U.S. Pat. No. 6,187,036 (titled ENDOLUMINAL VASCULAR PROSTHESIS and filed on Dec. 11, 1998), U.S. Pat. No. 6,197,049 (titled ARTICULATING BIFURCATION GRAFT and filed on Feb. 17, 1999), U.S. Pat. No. 6,500,202 (titled BIFURCATION GRAFT DEPLOYMENT CATHETER and filed on Mar. 15, 2000), U.S. Pat. No. 6,660,030 (titled BIFURCATION GRAFT DEPLOYMENT CATHETER and filed on Dec. 22, 2000), or U.S. Pat. No. 6,733,523 (titled IMPLANTABLE VASCULAR GRAFT and filed on Jun. 26, 2001). The entirety of each of the above-listed patents are hereby incorporated by reference as if fully set forth herein.


For example, in some embodiments, the main body graft 12 and/or the branch graft 14 can be expanded using an uncovered (i.e., bare) self-expanding metal frame or a self-expanding metal frame covered with a thin graft material, which can be made from ePTFE, as disclosed in U.S. Pat. No. 6,077,296. However, the specific design and selection of the materials, shapes, or other aspects for the main body graft 12 or the branch graft 14 of the endoluminal prosthesis 10 is not limited to the designs and configurations disclosed or incorporated by reference herein, but can be based on any suitable variety of materials, shapes, or other aspects of any other suitable endoluminal prostheses. Additionally, the main body graft 12 and/or the branch graft 14 (or any other main or branch graft disclosed herein) can be expanded using a mechanical expander, and be held in the expanded position against the blood vessel wall by the blood pressure within the vessel (i.e., without the use of a stent).


In some embodiments, the main body graft 12 can comprise an expandable metal frame to support the main body graft 12 within the aorta (not illustrated). The frame supporting the main body graft 12 of the endoluminal prosthesis 10 can be formed from a metal or any other suitable material, and can be configured so as to not obstruct the flow of blood through the opening 14b in the branch graft or grafts 14. The metal frame can comprise a self-expandable structure comprising one or more wires forming a zig-zag, tubular shape, as described above with reference to U.S. Pat. Nos. 6,077,296, 6,187,036, 6,197,049, 6,500,202, 6,660,030 and/or 6,733,523. In some embodiments, the metal frame can be formed by laser cutting a tubular structure. Such structures are well known in the art. However, those of skill in the art will recognize that various configurations and constructions of the frame can be used in light of the disclosure herein.



FIG. 2 is a partial section view of a portion of the embodiment of the endoluminal prosthesis 10 illustrated in FIG. 1A, after the branch graft portion 14 of the endoluminal prosthesis 10 has been positioned within a branch vessel artery (represented by BV in FIG. 2). FIG. 3 is a partial section view of a portion of the embodiment of the endoluminal prosthesis 10 illustrated in FIG. 1A, showing a balloon expandable stent being positioned within the partially expanded branch graft 14 of the endoluminal prosthesis 10. FIG. 4 is a partial section view of a portion of the embodiment of the endoluminal prosthesis 10 illustrated in FIG. 1A, showing a balloon expandable stent being expanded within the branch graft 14 of the endoluminal prosthesis 10. FIG. 5 is a partial section view of a portion of the embodiment of the endoluminal prosthesis 10 illustrated in FIG. 1A, showing an expanded stent positioned within a branch graft 14 of the endoluminal prosthesis 10.


With reference to FIGS. 2-5, one method of positioning and implanting the fully assembled endoluminal prosthesis 10 in the desired aortic location will now be described. After advancing a guidewire 18 through the vasculature into the desired branch vessel BV by known or suitable methods, the partially expanded branch graft 14 of the endoluminal prosthesis 10 can be guided over the guidewire 18 so that the main body graft 12 is positioned within the desired location in the aorta and the branch graft 14 is positioned in the desired branch vessel (represented by BV in FIG. 2).


With reference to FIG. 3, once the partially expanded branch graft 14 is positioned within the desired branch vessel BV, a balloon-expandable stent 20 can be guided over the guidewire 18 and positioned inside the partially expanded branch graft 14. As shown in FIG. 4, the balloon expandable stent 20 can be expanded by the expansion of a balloon 22 positioned within the balloon expandable stent 20. Once the stent 20 of the branch graft 14 has been expanded by the balloon 22, a balloon 22 can be deflated, leaving the expanded stent 20 positioned within the branch graft 14, as illustrated in FIG. 5.


The main body graft 12 and/or branch graft 14 the can be expanded and secured in the desired position by any other suitable method for such. Suitable expansion apparatuses and methods include, but are not limited to, balloon catheters, dilators, and self-expanding stents or stent grafts. Other means of securing the main body graft 12 and/or branch graft 14 may include, without limitation, self-expanding stents, stent grafts, sutures, and staples.


In some embodiments, the stent 20 can be a bare wire stent of any configuration described above or incorporated herein by reference. In some embodiments, the stent 20 can be a graft covered stent, also of any configuration described above or incorporated herein by reference. A graft covered stent can provide a greater degree of safety to the patient by providing a double layer graft system that can be less prone to tearing or other damage.


In some arrangements, after the branch stent 20 and the branch graft 14 have been expanded within the desired branch vessel, the main body graft 12 may thereafter be expanded within the aorta. In some arrangements, the main body graft 12 can be expanded within the aorta prior to expanding the branch stent 14 within the branch vessel BV. The main body graft 12 can be expanded and held in the desired position using a self-expandable stent, or can be expanded and held in position by any other suitable stent device, such as without limitation, a balloon expandable stent. As such, similar to the branch graft 14, the main body graft 12 can be expanded and held in position with a bare metal stent or a covered stent, or any of the stents described or incorporated by reference herein.


Some embodiments of the endoluminal prosthesis 10 can be implanted within the desired vessel in a multistep process, such that an integrated deployment mechanism is not used for such embodiments of the endoluminal prosthesis 10. The expansion and stenting of the branch graft 14 can be performed in a secondary procedure, after the branch graft 14 has been positioned in the desired blood vessel.


As mentioned, in certain situations, several vessels may branch off from the main blood vessel in the location that is desired to be stented. In this case, the endoluminal prosthesis 10 can be formed with multiple branch grafts 14 formed therein or secured thereto. For example, the two renal arteries and the superior mesenteric artery (“SMA”) generally branch off from the aorta in close proximity to each other. The positions of the branch vessels generally vary from patient to patient, as shown in FIG. 6, which is a graphical illustration of the location of the two renal arteries with respect to the SMA in 50 patients undergoing an abdominal aortic aneurysm (AAA) procedure. For reference, the SMA is located at the origin of the graph. The locations of the left and right renal arteries are expressed in terms of axial distance from the SMA in millimeters (x-axis), and circumferential angle from the SMA (y-axis). As FIG. 6 illustrates, there is typically a large variability in the locations of the vessels from one patient to the next.



FIG. 6 indicates that, in case of stent grafting across the renal arteries, the small and the large opening are approximately 180 degrees opposite to each other. In some embodiments, the large opening can be sufficiently large to accommodate an axial distance between the renal arteries of between approximately 15 mm and approximately 20 mm, and a circumferential asymmetry of +/−20 degrees. Thus, in some embodiments, the large opening may have a diameter of approximately 20 mm.



FIGS. 7A and 7B are a front view and a section view, respectively, of another embodiment of an endoluminal prosthesis 30 having a main body graft 32 and a branch graft 34. FIGS. 8A, 8B, and 8C are a perspective view, top view, and section view, respectively, of another embodiment of an endoluminal prosthesis 40 having a main body graft 42 and a branch graft 44.


The embodiments of the endoluminal prostheses in FIGS. 7A-8B can be configured for application in portions of the body other than in the portions of the aorta described above. For example, some embodiments of the endoluminal prosthesis 30 illustrated in FIGS. 7A, 7B can be configured for application in a specific artery or arteries. In particular, without limitation, the embodiment of the endoluminal prosthesis 30 illustrated in FIGS. 7A, 7B can be configured for use in the thoracic aorta, with the branch graft 34 configured for positioning within the subclavian artery. As illustrated, in FIGS. 7A, 7B, the main body graft 32 can define curved portion that may be suitable for curved vessels such as that of the subclavian artery. Other aspects of the endoluminal prosthesis 30 can be the same as or similar to any of the other endoluminal prostheses disclosed herein, and the endoluminal prosthesis 30 can be deployed and secured in the desired artery by any of the same methods as described above with respect to endoluminal prosthesis 10.


Similarly, some embodiments of the endoluminal prostheses 40 illustrated in FIGS. 8A, 8B can also be configured for application in a specific artery or arteries. For example, without limitation, the embodiments of the endoluminal prosthesis 40 illustrated in FIGS. 8A, 8B can be configured for use in the iliac artery, with the branch graft 44 configured for positioning within the hypogastric artery or arteries. However, there are many locations in the body that would benefit from a placement of a branch graft systems or endoluminal prostheses disclosed herein to ensure perfusion of branch vessels, and none of the embodiments of the endoluminal prostheses disclosed herein are confined to any particular portion of the body. The examples described with regard to FIGS. 7A-8B merely serve as illustrations of potential applications of such a branch graft system. Other aspects of the endoluminal prosthesis 40 can be the same as or similar to any of the other endoluminal prostheses disclosed herein, and the endoluminal prosthesis 40 can be deployed and secured in the desired artery by any of the same methods as described above with respect to endoluminal prosthesis 10.


The issue of variability in the anatomy has been overcome in the past by providing custom-made fenestrated grafts in which the openings (commonly referred to as fenestrations) are formed in the main body graft, which were generally custom-made to fit vessels of the individual patient. One disadvantage of custom making the fenestrated grafts after examining the individual patients vascular anatomy is that, as mentioned, the patient's anatomy is generally required to be closely examined using imaging scans prior to fabricating the fenestrated graft. Subsequently, image analysis is typically required to be performed to determine the geometrical relationship between the particular patient's main vessel and the branch vessels. This generally required the medical practitioner to individually build or modify the endoluminal prosthesis to create fenestrations at the appropriate location of the branch vessels. The custom-made graft then is generally required to be placed exactly in the correct location in the blood vessel to ensure that the fenestrations are properly aligned with the branch vessel. Another disadvantage is that this can be a multi-step, time consuming procedure. It is not uncommon to require several months to prepare a custom-made graft for the patient. Additionally, the deployment of a custom-made endoluminal prosthesis can be very difficult, typically requiring a high skill level in endovascular procedures.


The following embodiments present additional alternatives to the custom-made fenestrated grafts discussed above. FIGS. 9A and 9B are a perspective view and a side view, respectively, of an embodiment of a fenestrated endoluminal prosthesis or graft 50. As illustrated in FIGS. 9A, 9B, the fenestrated graft 50 can have two openings or fenestrations 52a, 52b formed in the main graft 50. Any of a wide ranging variety of fenestrated grafts 50 can be manufactured, each having a different location of the two openings or fenestrations 52a, 52b formed therein so that the doctor can select the appropriately configured fenestrated graft 50 depending on the patient's particular vasculature.



FIGS. 10A and 10B are a perspective view and a side view, respectively, of an embodiment of a fenestrated endoluminal prosthesis 60 (also referred to herein as a first endoluminal prosthesis or graft), which present an alternative to the custom-made fenestrated grafts discussed above. To facilitate and description of some of the embodiments disclosed herein, the placement of the fenestrated endoluminal prosthesis 60 at the renal arteries is described. However, the embodiments of the fenestrated endoluminal prostheses 60 disclosed herein are not limited to this particular location or application. This application merely serves as an example to illustrate the basic aspects of the fenestrated endoluminal prosthesis 60.


In some embodiments, the endoluminal prosthesis 60 can comprise a main body 62 and first and second openings 64, 66, respectively. The main body 62 can have an inside surface 62a and an outside surface 62b. In some embodiments, the endoluminal prosthesis 60 can comprise any suitable or desired number of openings. For example, without limitation, the endoluminal prosthesis 60 can have one or more openings or cutouts (not illustrated) in addition to the openings 64, 66 illustrated in FIGS. 10A, 10B to account for other renal or branch arteries that may otherwise be covered by the main body 62 of the endoluminal prosthesis 60.


In the embodiment of the endoluminal prosthesis 60 illustrated in FIGS. 10A, 10B, the openings 64, 66 can be positioned at mutually or diametrically opposing locations. However, the openings 64, 66 can be positioned at any desired or suitable axial or radial position. Additionally, in the embodiment of the endoluminal prosthesis 60 illustrated in FIGS. 10A, 10B, the openings 64, 66 can have a circular shape. However, the openings 64, 66 can have any desired or suitable shape, including square, rectangular, polygonal, or otherwise.


Further, in the illustrated embodiment where each of the openings are generally circular, the diameter of the second opening 66 can be approximately four times greater than the diameter of the first opening 64. In some embodiments, the diameter of the second opening 66 can be between approximately two times greater and approximately four times greater, or between approximately four times greater and approximately six times or more greater than the diameter of the first opening 64. Additionally, in some embodiments, the second opening 66 can be configured to be as large as is possible to cover a wide range of branch vessel anatomies. As the size of the second opening 66 is increased, the potential to treat a large range of branch vessel anatomies is also increased.


Similarly, in some embodiments where the openings are non-circular, the width and/or height of the second opening 66 can be approximately four times greater than the width and/or height of the first opening 64. In some embodiments, the width and/or height of the second opening 66 can be between approximately two times greater and approximately four times greater, or between approximately four times greater and approximately six times or more greater than the width and/or height of the first opening 64.


In some embodiments, similar to any other prosthesis disclosed herein, the prosthesis 60 can be self-expanding, balloon expandable, or can be of any other suitable configuration. The openings 64, 66 can be configured to be positioned adjacent to the two renal arteries. The first opening 64 can approximately match the size of the first renal artery, while the second opening 66 can be substantially larger that the first opening 64. As will be described in greater detail below, the size of the second opening 66 can be greater than the size of the first opening 64 to account for the variability in the location of the second renal artery with respect to the first renal artery. In this configuration, the endoluminal prosthesis 60 can be positioned within the patient's vasculature so that the main body 62 of the endoluminal prosthesis 60 does not cover the second renal when the first opening 64 of the main body 62 is aligned with the patient's first renal artery.


As will be described in greater detail below, to seal the area around the second renal artery after the first endoluminal prosthesis 60 has been positioned in the patient's vasculature, another fenestrated endoluminal prosthesis 70 (also referred to herein as a second endoluminal prosthesis or graft) comprising a main body 72, a first or smaller opening 74, and a second or larger opening 76, can be inserted into the patient's vasculature on the inside of the first endoluminal prosthesis 60. FIGS. 11A and 11B are a perspective view and a side view, respectively, of the embodiment of the fenestrated endoluminal prosthesis 70. The main body 72 can have an inside surface 72a and an outside surface 72b.


The first or smaller opening 74 of the second endoluminal prosthesis 70 can be positioned within the patient's vasculature so as to be aligned with the patient's second renal artery. The second or larger opening 76 of the second endoluminal prosthesis 70 can ensure that the first renal artery is not covered by the main body 72 of the second endoluminal prosthesis 70. The second, larger opening 66 in the first endoluminal prosthesis 60 and the second, larger opening 76 in the second endoluminal prosthesis 70 can allow for greater variability in the location of the renal arteries, without requiring a medical practitioner to custom make the prosthesis.


In particular, after the first endoluminal prosthesis 60 has been positioned in the patient's vasculature so that the outside surface 62b can expand against and contact the walls of the patient's artery and so that the first or smaller opening 64 is approximately aligned with the first renal artery and the second or larger opening 66 is sufficiently aligned with the second renal artery so that the main body 62 does not cover the second renal artery, the second endoluminal prosthesis 70 can be positioned within the patient's vasculature so that the first or smaller opening 74 is approximately aligned with the patient's second renal artery and the second or larger opening 76 is sufficiently aligned with the first renal artery so that the main body 72 does not cover the first renal artery. The second endoluminal prosthesis 70 can then be expanded so that the outside surface 72b of the main body 72 of the second endoluminal prosthesis 70 is in contact with the inside surface 62a of the main body 62 of the first endoluminal prosthesis 60.


In some embodiments, the second endoluminal prosthesis 70 can be the same as or similar to the first endoluminal prosthesis 60 including, but not limited to, having the same number, size, and location of the openings as are in the first endoluminal prosthesis 60. In some embodiments, the second endoluminal prosthesis 70 can have a different configuration as compared to the first endoluminal prosthesis 60 including, but not limited to, having a different number, size, and/or location of the openings that are formed in the main body 72 of the second endoluminal prosthesis 70.


Again, the size and shape of the openings 64, 66, 74, 76 are not limited to the illustrations or the description set forth above, but can be any suitable size or shape, or can be positioned at any suitable location on the endoluminal prosthesis 60, 70, respectively. Additionally, the size, shape, or other aspects of the configuration of the endoluminal prostheses 60, 70 are not limited to the specific embodiments described or illustrated herein. The endoluminal prostheses 60, 70 can comprise any suitable size, shape, including openings or cutouts (i.e., scallops) formed in the proximal and/or distal ends thereof or other aspects of other suitable configurations known or later developed in the field including, but not limited to, other known expandable non-bifurcated and bifurcated prostheses. For example, without limitation, in some embodiments, the main body 62, 72 of the prostheses 60, 70, respectively, can comprise any of the materials, features, or other aspects of the embodiments of the endoluminal vascular prostheses disclosed in U.S. Pat. Nos. 6,077,296, 6,187,036, 6,197,049, 6,500,202, 6,660,030 and/or 6,733,523, the entirety of which are hereby incorporated by reference as if fully set forth herein.


Without limitation, in some embodiments, the main body 62, 72 of the endoluminal prostheses 60, 70 may comprise any of the materials, shapes, or other aspects of the polymeric sleeves and/or the tubular wire supports disclosed in U.S. Pat. Nos. 6,077,296, 6,187,036, 6,197,049, 6,500,202, 6,660,030 and/or 6,733,523. However, the specific design and selection of the materials, shapes, or other aspects for each of the main bodies 62, 72 of the endoluminal prostheses 60, 70 are not limited to those set forth in patents set forth above, but can be based on any suitable variety of materials, shapes, or other aspects of any other suitable endoluminal prostheses. In addition, the techniques and constructions of U.S. Pat. Nos. 6,187,036, 6,197,049, 6,500,202, 6,660,030 and/or 6,733,523, the entire contents of which are hereby incorporated by reference herein, can also be used and/or adapted for use with the main body 62, 72.


With reference to FIGS. 12-19, the deployment of the fenestrated endoluminal prosthesis system described above will be described in greater detail. FIG. 12 is a partial section view of the endoluminal prosthesis 60 illustrated in FIGS. 10A, 10B positioned within an embodiment of a delivery catheter 78. FIG. 13 is a side view of the embodiment of the endoluminal prosthesis 60 illustrated in FIGS. 10A, 10B before the endoluminal prosthesis 60 is placed in a delivery catheter 78. With reference to FIGS. 12, 13, the hollow guidewires 80, 82 can be placed through the openings 64, 66, respectively, of the endoluminal prosthesis 60. In some embodiments, the guidewires 80, 82 can be made from a plastic extrusion or metal braids. For example, in some embodiments, the hollow guidewires 80, 82 can be made from braided Nitinol wire. In some embodiments, the outer diameter of the guidewires 80, 82 can be approximately 0.035 in and the lumen of the guidewire can be approximately 0.016 in to accommodate a second 0.014 in guidewire. In some embodiments, the guidewires 80, 82 can be configured to pass over a 0.018 in or any other suitable guidewire. FIG. 14 is a partial section view of a patient's vasculature illustrating guidewires 90, 92 inserted through the abdominal aortic 94 and into the renal arteries 96, 98, respectively.


In some embodiments the guidewires 80, 82 can support balloons on the distal end of the guidewires 80, 82. The balloons can be inflated in the branch vessel to removably anchor or support the guidewire 80, 82 against the vessel wall and prevent inadvertent removal of the guidewires from the branch vessels during the deployment procedure. In some embodiments, for example, one or more occlusion balloon catheters can be used. Other anchoring mechanisms can be attached to the guidewire, such as, without limitation, hooks, to removably secure one or more of the guidewires 80, 82 within or to the vessel.


Additionally, in some embodiments, one of more of the guidewires disclosed herein (such as, without limitation, guidewires 80, 82) can have a coiled distal end portion. The coiled distal end portion can be configured to be insertable into a branch vessel and can be biased to remain in the branch vessel. In particular, in some embodiments, the size or diameter of the coils can be greater than the inside diameter of the branch vessel so as to bias the coiled portion to remain within the branch vessel when the proximal end of the guidewire is retracted. In this configuration, proximal retraction of the guidewire can cause a proximal end of the coil to unravel, allowing a portion of the coiled portion of the guidewire to be unraveled and retracted while the remaining portion of the coiled portion can remain within the branch vessel. This configuration can inhibit the distal end portion of the guidewire from being inadvertently removed from the branch vessel. To completely remove the coiled distal end portion from the branch vessel, the guidewire can be retracted until the entire coiled portion is unraveled and retracted.


In some embodiments, the length of the coiled portion can be approximately 6 cm. In some embodiments, the length of the coiled portion can be between approximately 3 cm or less and approximately 5 cm, or between approximately 5 cm and approximately 7 cm, or between approximately 7 cm and approximately 9 cm or more, or from or to any values in these ranges. In some embodiments, the unraveled length of the coiled portion can be approximately 20 cm. In some embodiments, the unraveled length of the coiled portion can be between approximately 10 cm or less and approximately 15 cm, or between approximately 15 cm and approximately 20 cm, or between approximately 20 cm and approximately 25 cm or more, or from or to any values in these ranges.


However, the guidewires 80, 82 or any other guidewires disclosed herein can have any desired or suitable configuration. For example, the guidewires 80, 82 or any other guidewires disclosed herein can have the same or similar materials, configurations, methods of fabrication, and other aspects or details as the hollow guidewires set forth in U.S. Patent Application Publication No. US 2004-0098087 A1, titled DUAL WIRE PLACEMENT CATHETER (application Ser. No. 10/706,660), filed on Nov. 12, 2003, and U.S. application Ser. No. 11/623,022, titled DUAL CONCENTRIC GUIDEWIRE AND METHODS OF BIFURCATED GRAFT DEPLOYMENT, filed on Jan. 12, 2007, the entirety of both of which are incorporated by reference herein as if fully set forth herein.


With reference to FIG. 12, the collapsed endoluminal prosthesis 60 can be supported within the outer sheath 84 of the delivery catheter 78 in the space between the catheter shaft 86 and the catheter tip 88. In some embodiments, the hollow guidewires 80, 82 can slide through openings or lumens in the catheter shaft 86. Alternatively, in some embodiments, the hollow guidewires 80, 82 can be fixed to the catheter shaft 86.


The hollow guidewires 80, 82 can pass through the outer sheath 84 from the proximal end of the delivery catheter 78 to the distal end of the delivery catheter 78. Each of the hollow guidewires 80, 82 can be configured to receive or allow the insertion of 0.014 in guidewire therethrough. In this configuration, the hollow guidewires 80, 82 can pass over guidewires 90, 92 that can be pre-placed in the appropriate vasculature.


In this configuration, the endoluminal prosthesis 60 can be retained in the delivery catheter 78 by the outer sheath 84. As will be described in greater detail, retraction of the outer sheath 84 can deploy the endoluminal prosthesis 60. With the outer sheath 84 retracted, the endoluminal prosthesis 60 can expand either by self-expansion, balloon expansion, or by any other suitable method or mechanism. FIG. 15 is a perspective view of the embodiment of the endoluminal prosthesis 60 illustrated in FIGS. 10A, 10B in the deployed or expanded state (i.e., after the outer sheath 84 of the catheter 78 has been retracted and of the endoluminal prosthesis 60 has been expanded). FIG. 15 also shows the guidewires 80, 82 passing through the openings 64, 66 respectively. As can be seen in FIG. 15, in some embodiments, the catheter 78 can have three lumens through at least a portion of the catheter 78, each of the three lumens configured to receive a guidewire. Having three lumens through at least a portion of the catheter 78 can prevent twisting of the guidewires, so as to ensure proper deployment.


As again illustrated in FIG. 15, each of the 0.014 in guidewires 90, 92 can be passed through the hollow guidewires 80, 82, respectively. Therefore, before placing the endoluminal prosthesis 60 across the renal arteries, the guidewires 90, 92 can be maneuvered into the target vessels, as shown in FIG. 14, which is a partial section view of a patient's vasculature illustrating guidewires 90, 92 inserted through the abdominal aortic 94 and into the renal arteries 96, 98, respectively.


As illustrated in FIG. 14, third guidewire 100 can be positioned in the aorta 94 at the same time that the 0.014 in guidewires 90, 92 can be placed in the left and the right renal arteries 96, 98, respectively. The delivery catheter 78 can then be passed over guidewire 100 into the aorta. The hollow guidewires 80, 82 of the delivery system can track over the guidewires 90, 92 into the renal arteries until the endoluminal prosthesis 60 is positioned in the desired location.



FIG. 16 is a partial section view of a patient's vasculature illustrating the endoluminal prosthesis 60 deployed in the desired position within the patient's vasculature, after the components of the delivery catheter 78 except for the guidewires 80, 82 have been retracted from the patient's vasculature. As has been described, the hollow guidewire 80 can pass over the guidewire 90 through the opening 64 into the right renal artery 98. The hollow guidewire 82 can pass over the guidewire 92 through the opening 66 into the left renal artery 96.


In some embodiments, sutures or markers made from an RO material can be sewn into or attached to the endoluminal prosthesis 60 or any other prosthesis disclosed herein adjacent to the openings formed therein or at any other suitable location to assist the medical practitioner in visualizing the location of the prosthesis relative to the patient's vasculature. For example, without limitation, RO sutures can be sewn into the main body 62 of the endoluminal prosthesis 60 around each of the openings 64, 66 and/or near the end portion or portions of the main body 62. Alternatively, RO markers can be sewn to or otherwise attached to the main body of the endoluminal prosthesis 60 or any endoluminal prosthesis at any suitable position.



FIG. 17 is a partial section view of a patient's vasculature illustrating the endoluminal prosthesis 60 illustrated in FIGS. 10A, 10B deployed in the desired position within the patient's vasculature, after all of the components of the delivery catheter 78 have been retracted from the patient's vasculature, including the hollow guidewires 80, 82. The guidewires 90, 92 can remain in position in the renal arteries. As illustrated in FIG. 17, the first, smaller opening 64 of the endoluminal prosthesis 60 can be approximately aligned with the right renal artery 98. As mentioned, the first opening 64 can approximately match the size of the opening into the right renal artery 98. Additionally, with reference to FIG. 17, the second, larger opening 66 of the endoluminal prosthesis 60 can be positioned so that the main body 62 of the endoluminal prosthesis 60 does not cover or inhibit the flow of blood from the aortic artery 94 into the left renal artery 96.



FIG. 18 is a partial section view of a patient's vasculature illustrating the endoluminal prosthesis 70 illustrated in FIGS. 11A, 11B also deployed in the desired position within the patient's vasculature, after the components of the delivery system except for the guidewires have been retracted from the patient's vasculature. In FIG. 18, a second endoluminal prosthesis 70 has been positioned in the desired location in a similar fashion as has been described above with respect to the first endoluminal prosthesis 60. Again the hollow guidewires 102, 104 of the second delivery system can pass over the guidewires 90, 92, respectively. The opening 74 (which, again, can be relatively small as compared to opening 76) in the second endoluminal prosthesis 70 can be placed adjacent to the left renal artery 96. The opening 76 (which can be relatively large as compared to the first opening 74) in the second endoluminal prosthesis 70 can be placed adjacent to the right renal artery 98.



FIG. 19 is a partial section view of a patient's vasculature illustrating both endoluminal prostheses 60, 70 positioned in the desired position within the patient's vasculature, after the components of the delivery system or systems have been retracted from the patient's vasculature. The small openings 64, 74 of the respective endoluminal prostheses 60, 70 provide fenestration to both renal arteries 98, 96, respectively. The overlapping endoluminal prostheses 60, 70 ensure a seal of the graft against the aorta. Thereafter, an expandable stent can be positioned and expanded within the endoluminal prostheses 60, 70, in a manner that is similar to the expandable stents described above, or in any suitable manner. While the prostheses 60, 70 are described as being self-expandable, in modified embodiments, one or both of the prostheses 60, 70 can be partially or wholly balloon expandable, or expandable by any other means.



FIG. 20 is a perspective view of another embodiment of a fenestrated graft or endoluminal prosthesis 110 with a scalloped end portion. With reference to FIG. 20, the endoluminal prosthesis 110 can have a main body 112, a first, smaller opening 114, a second, larger opening 116, and one or more cutouts 118 (two being shown) formed at any desired location in an end portion of the main body 112 or at any location in the main body 112. In some embodiments, with the exception of the differences discussed herein and/or illustrated in FIG. 20, other aspects of the endoluminal prosthesis 110 can be the same as or similar to any of the other endoluminal prostheses disclosed herein, including but not limited to the endoluminal prostheses 10, 60 disclosed herein. Furthermore, the endoluminal prosthesis 110 can be deployed and secured in the desired vascular location by any of the same methods as described above with respect to any other endoluminal prostheses, including but not limited to the endoluminal prostheses 10, 60. The one or more cutouts 118 can be sized and position so that the main body 112 of the endoluminal prosthesis 110 does not significantly obstruct the flow into any other branch arteries.


For example, the cutouts 118 can be advantageous when positioning the endoluminal prosthesis 110 in the vasculature below the SMA. Any of the endoluminal prostheses or other grafts disclosed in this application or incorporated by reference herein can be formed so as to comprise the one or more cutouts 118 illustrated in FIG. 20. Again, in some embodiments, sutures or markers made from an RO material can be sewn into or attached to the endoluminal prosthesis 110 or any other prosthesis disclosed herein adjacent to one or more of the cutouts 118, one or more of the openings 114, 116 formed therein, near either of the end portions of the main body 112, or at any other suitable location.



FIG. 21 is a perspective view of another embodiment of an endoluminal prosthesis 120. In some embodiments, certain aspects of the endoluminal prosthesis 120 can be the same as or similar to any of the other endoluminal prostheses disclosed herein, including but not limited to the endoluminal prostheses 10, 60, 110 disclosed herein. Similar to the prosthesis 10 illustrated in FIG. 1A, the endoluminal prosthesis 120 can have a main body 122 and a branch graft 124. Additionally, similar to the prosthesis 60 disclosed herein, the endoluminal prosthesis 120 can have a larger opening 126 formed in the main body 122 at any desired axial or radial position. In some embodiments, the larger opening 126 can be positioned on the main body 122 at a radial position that opposes the branch graft 124 such that the axial centerline of the larger opening 126 is approximately parallel to the axial centerline of the branch graft 124.


In some embodiments, the branch graft 124 can be integrally formed with or can be sutured, adhered, or otherwise attached to the main body 122 in place of the first, smaller opening 64 described above with reference to endoluminal prosthesis 60. Accordingly, in some embodiments, the endoluminal prosthesis 120 can be deployed in the same manner as or similar to the method described above for deploying the endoluminal prosthesis 60. Alternatively, the endoluminal prosthesis 120 can be deployed by any suitable method. Similar to the embodiment of the endoluminal prosthesis 110 illustrated in FIG. 20, the endoluminal prosthesis 21 can also have one or more cutouts 118 (not shown) formed at any desired location in an end portion of the main body 122. Further, as with any other endoluminal prosthesis disclosed herein, in some embodiments, sutures or markers made from an RO material can be sewn into or attached to the endoluminal prosthesis 120 adjacent to one or more of the cutouts 118 (not illustrated), adjacent to the opening 126 formed in the main body 122, adjacent to or on the branch graft 124, near either of the end portions of the main body 112, and/or at any other suitable location.


With reference to FIGS. 22-27, a method of deploying the endoluminal prosthesis 120 will now be described. FIG. 22 is a partial section view of a patient's vasculature after a first and second endoluminal prosthesis 120, 130 have been positioned within the patient's vasculature, after the components of the delivery system except for the hollow guidewires 80, 82 have been retracted from the patient's vasculature. In some embodiments, as illustrated in FIG. 22, the second endoluminal prosthesis 130 can be the same as the first endoluminal prosthesis 120 described above. Further, with reference to FIG. 22, the branch graft 124 of the first endoluminal prosthesis 120 can be positioned in the right renal artery 98, while the branch graft 134 of the second endoluminal prosthesis 130 can be positioned within the left renal artery 96.


Similar to the fenestrated endoluminal prostheses described above, each endoluminal prosthesis 120, 130 is independently positionable so as to accommodate a wide range of vasculature geometries or renal arteries without requiring a medical practitioner to custom make the endoluminal prosthesis. In some embodiments, the branch graft 124, 134 in the endoluminal prostheses 120, 130 can be sized to match the renal artery or branch vessel that the branch graft 124, 134 is intended to be inserted into. The position and size of the second larger opening can be configured such that it accommodates a wide range of branch vessel configurations.


Similar to the deployment of the endoluminal prostheses 60, 70 described above, the guidewires 90, 92 can be used for positioning each of the endoluminal prostheses 120, 130, and for guiding the delivery catheter for each of the branch stents, as will be described below. FIGS. 23 and 24 are partial section views of a patient's vasculature illustrating the endoluminal prostheses 120, 130 deployed in the desired position within the patient's vasculature, further illustrating a branch graft deployment catheter 140 being guided into the right renal artery 98 over the guidewire 90. With reference to FIGS. 23 and 24, after the first and second endoluminal prostheses 120, 130 have been positioned in the desired location in the patient's vasculature, the branch graft deployment catheter 140 can be guided up the guide wire 90 into the right renal artery 98. Optionally, if the branch graft deployment catheter has a balloon supported by the distal end thereof, the balloon can be inflated to secure the branch graft deployment catheter within the renal artery, as discussed above. Additionally, in some embodiments, coils or hooks supported by the distal end of the branch graft deployment catheter can be used to secure the branch graft deployment catheter within the renal artery.


Once the deployment catheter 140 has reached the desired position such that the catheter tip 142 has extended past the end of the branch graft 124, as illustrated in FIG. 24, the outer sheath 144 of the deployment catheter 140 can be retracted to deploy the stent 146 supported within the deployment catheter 140, as illustrated in FIG. 25. The stent 146 illustrated in FIG. 24 is a self expanding stent. However, the procedures disclosed herein can easily be modified to accommodate a balloon expandable or other stent suitable for such use.


As mentioned above, FIG. 25 is a partial section view of a patient's vasculature illustrating an embodiment of a stent 146 being deployed in the branch graft 124 positioned in a patient's right renal artery 98 by proximally retracting the outer sheath 144 of the deployment catheter 140. FIG. 26 illustrates the patient's vasculature after the stent 142 has been completely deployed in the branch graft 124 positioned in a patient's right renal artery 98. As illustrated therein, the expansion of the stent 146 can cause the branch graft 124 to expand against the blood vessel 98, so as to secure the graft 124 in the desired position. Note that, in some embodiments, the proximal portion of the branch graft 124 (i.e. a portion of the branch graft 124 closest to the main body 122 of the endoluminal prosthesis 120, as illustrated in FIG. 25) can be pre-expanded to more approximately match the patient's vasculature in the pre-deployed state, as was described above with reference to endoluminal prosthesis 10.


Finally, FIG. 27 is a partial section view of a patient's vasculature illustrating an embodiment of a stent 142 after it has been completely deployed in the branch graft 124 positioned in a patient's right renal artery 98, further illustrating the delivery catheter 140 being removed from the patient's vasculature. Following the procedures described in connection with FIGS. 22-27, a stent similar to the stent 146 described above can be deployed in the branch graft 134 of the second endoluminal prosthesis 130, so that the branch graft 134 in the left renal artery 96 can be supported in the desired position.


Alternatively, the branch grafts 124, 134 can be expanded within the renal artery in a manner similar to any of the methods disclosed herein for expanding the branch graft 14 in the blood vessel or renal artery. Alternatively, the branch grafts 124, 134 can be expanded within the blood vessel or renal artery following any other suitable method, which can include deploying a self-expanding or balloon expandable bare metal stent or graft covered stent therein after the branch grafts 124, 134 have been positioned in the desired blood vessel or renal artery.


Additionally, any of the endoluminal prostheses described herein can be used independently or can be used in conjunction one or more additional grafts, including the grafts disclosed herein or any other suitable grafts such as other tubular or bifurcated grafts. For example, without limitation, any of the endoluminal prostheses disclosed herein or incorporated herein by reference, or either or both of the endoluminal prostheses 120, 130 can be used in conjunction with an additional prosthesis configured the same as or similar to the endoluminal prosthesis 120 to accommodate additional branch vessels, and/or any other suitable prostheses, such as without limitation a bifurcated prosthesis.


Additionally, without limitation, any of the endoluminal prostheses disclosed herein or incorporated herein by reference, or either or both of the endoluminal prostheses 120, 130 can be used with any bifurcated graft positioned in a patient's vasculature to protect a patient's AAA. In this application, one or more of the endoluminal prostheses disclosed herein (including but not limited to endoluminal prostheses 10, 30, 40, 50, 60, 70, 110, and/or 120) can be deployed within the patient's vasculature after the bifurcated graft has been deployed across the patient's AAA. In this manner, the endoluminal prostheses disclosed herein will be positioned within the bifurcated graft it has been deployed across the patient's AAA so as to minimize or prevent blood from flowing between the main tubular portion of the bifurcated graft and the patient's blood vessel.


One of ordinary skill in the art will recognize many configurations of the fenestrated grafts described herein for the treatment of a main vessel having two or more branch vessels. As described herein, in some embodiments, the overlap of two or more portions of the endoluminal prostheses each having at least one small and one large opening can combine to create an endoluminal prosthesis system with two or more small openings, which can be used address a wide range of vasculature geometries without requiring any custom fabrication of the prostheses.


While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it will be understood that various omissions, substitutions, and changes in the form and details of the device or process illustrated can be made without departing from the spirit of the disclosure. Additionally, the various features and processes described above can be used independently of one another, or can be combined in various ways. All possible combinations and subcombinations are intended to fall within the scope of this disclosure.


As will be recognized, certain embodiments described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of the inventions is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.


For example, while some embodiments of the delivery and graft systems are described herein with respect to the abdominal aortic artery, the delivery and graft systems can be used for repairing vasculature in other portions of the body, including but not limited to the SMA, the inferior mesenteric artery, or any other arteries or blood vessels in the body suitable for such procedures or apparatuses.

Claims
  • 1. A method of delivering an endoluminal prosthesis system, the method comprising: deploying a first endoluminal prosthesis in a main vessel, the first endoluminal prosthesis comprising a main body graft, a first end, a second end, a single lumen extending from the first end to the second end, a first lateral opening in a wall portion of the main body graft, and a second lateral opening in the wall portion of the main body graft;positioning a first hollow tubular member that passes over a first guidewire and supports a balloon on a distal end of the first hollow tubular member through the first lateral opening into a first branch vessel prior to deploying a distal end of the first endoluminal prosthesis;positioning a second hollow tubular member that passes over a second guidewire and supports a balloon on a distal end of the first hollow tubular member through the second lateral opening into a second branch vessel prior to deploying a distal end of the first endoluminal prosthesis;inflating the balloon on the distal end of the first hollow tubular member; and inflating the balloon on the distal end of the second hollow tubular member.
  • 2. The method of claim 1, wherein the first lateral opening is diametrically opposite the second lateral opening.
  • 3. The method of claim 1, further comprising deploying a second endoluminal prosthesis in the main vessel, the second endoluminal prosthesis comprising a main body graft, a portion of the main body graft of the second endoluminal prosthesis being deployed inside of the first endoluminal prosthesis, another portion of the main body graft of the second endoluminal prosthesis extending out of the first endoluminal prosthesis;deploying a first stent in the first branch vessel; anddeploying a second stent in the second branch vessel.
  • 4. The method of claim 3, further comprising delivering a first branch graft in the first branch vessel prior to deploying the first stent.
  • 5. The method of claim 4, further comprising delivering a second branch graft in the second branch vessel prior to deploying the second stent.
  • 6. The method of claim 4, wherein the first branch graft is connected to the main body of the first endoluminal prosthesis.
  • 7. The method of claim 3, wherein deploying the first stent comprises expanding the first stent with a balloon that extends into the first branch vessel.
  • 8. The method of claim 3, wherein the second endoluminal prosthesis comprises a bifurcated graft.
  • 9. The method of claim 1, wherein the first branch vessel is the left renal artery and the second branch vessel is the right renal artery.
PRIORITY CLAIM AND INCORPORATION BY REFERENCE

This application is a continuation of U.S. patent application Ser. No. 14/840,428, filed Aug. 31, 2015, (entitled “APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM”), which is a continuation of U.S. patent application Ser. No. 14/172,126, now U.S. Pat. No. 9,149,381, filed Feb. 4, 2014, (entitled “APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM”), which is a continuation of U.S. patent application Ser. No. 13/546,950, now U.S. Pat. No. 8,672,989, filed on Jul. 11, 2012 (entitled “APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM”), which is a continuation of U.S. patent application Ser. No. 12/390,346, now U.S. Pat. No. 8,221,494, filed on Feb. 20, 2009 (entitled “APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM”), which claims the benefit under 35 U.S.C. § 119 of U.S. Provisional Patent Application No. 61/030,913, filed Feb. 22, 2008 (entitled “METHOD OF PLACEMENT OF AN AORTIC GRAFT”), all of which are hereby incorporated by reference in their entirety as if fully set forth herein.

US Referenced Citations (819)
Number Name Date Kind
2127903 Bowen Aug 1938 A
2437542 Krippendorf May 1944 A
2845959 Sidebotham Aug 1958 A
2990605 Demsyk Jul 1961 A
3029819 Starks Apr 1962 A
3096560 Liebig Jul 1963 A
3805301 Liebig Apr 1974 A
3994149 Dahlman Nov 1976 A
4362156 Feller, Jr. et al. Dec 1982 A
4473067 Schiff Sep 1984 A
4497074 Ray et al. Feb 1985 A
4501263 Harbuck Feb 1985 A
4503568 Madras Mar 1985 A
4512338 Balko et al. Apr 1985 A
4525157 Vaillancourt Jun 1985 A
4562596 Kornberg Jan 1986 A
4580568 Gianturco Apr 1986 A
4592754 Gupte et al. Jun 1986 A
4617932 Kornberg Oct 1986 A
4756307 Crownshield Jul 1988 A
4795465 Marten Jan 1989 A
4800882 Gianturco Jan 1989 A
4816028 Kapadia et al. Mar 1989 A
4840940 Sottiurai Jun 1989 A
4856516 Hillstead Aug 1989 A
4878906 Lindemann et al. Nov 1989 A
4907336 Gianturco Mar 1990 A
4922905 Strecker May 1990 A
4981478 Evard et al. Jan 1991 A
4981947 Tomagou et al. Jan 1991 A
4994069 Ritchrt et al. Feb 1991 A
4994071 MacGregor Feb 1991 A
5019090 Pinchuk May 1991 A
5035706 Giantureo et al. Jul 1991 A
5064435 Porter Nov 1991 A
5078726 Kreamer Jan 1992 A
5104399 Lazarus Apr 1992 A
5108424 Hoffman, Jr. et al. Apr 1992 A
5116349 Aranyi May 1992 A
5123917 Lee Jun 1992 A
5133732 Wiktor Jul 1992 A
5135535 Kramer Aug 1992 A
5135536 Hillstead Aug 1992 A
5151105 Kwan-Gett Sep 1992 A
5156619 Ehrenfeld Oct 1992 A
5158545 Trudell et al. Oct 1992 A
5178634 Martinez Jan 1993 A
5197976 Herweck et al. Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5211658 Clouse May 1993 A
5246452 Sinnott Sep 1993 A
5256141 Gancheff et al. Oct 1993 A
5275622 Lazarus et al. Jan 1994 A
5282478 Fleischhaker et al. Feb 1994 A
5282824 Gianturco Feb 1994 A
5282860 Matsuno et al. Feb 1994 A
5304200 Spaulding Apr 1994 A
5314444 Gianturco May 1994 A
5314472 Fontaine May 1994 A
5316023 Palmaz et al. May 1994 A
5320602 Karpeil Jun 1994 A
5330500 Song Jul 1994 A
5342387 Summers Aug 1994 A
5354308 Simon et al. Oct 1994 A
5360443 Barone et al. Nov 1994 A
5366504 Andersen et al. Nov 1994 A
5370683 Fontaine Dec 1994 A
5387235 Chuter Feb 1995 A
5397355 Marin et al. Mar 1995 A
5403341 Solar Apr 1995 A
5405377 Cragg Apr 1995 A
5405378 Strecker Apr 1995 A
5414664 Lin et al. May 1995 A
5415178 Hsi et al. May 1995 A
5415664 Pinchuk May 1995 A
5423886 Arru et al. Jun 1995 A
5425765 Tiefenbrun et al. Jun 1995 A
5443477 Marin et al. Aug 1995 A
5443498 Fontaine Aug 1995 A
5443500 Sigwart Aug 1995 A
5453090 Martinez et al. Sep 1995 A
5458615 Klemm et al. Oct 1995 A
5462530 Jang Oct 1995 A
5464449 Ryan et al. Nov 1995 A
5464450 Buscemi et al. Nov 1995 A
5484444 Braunschweiler et al. Jan 1996 A
5489295 Piplani et al. Feb 1996 A
5496365 Sgro Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5507768 Lau et al. Apr 1996 A
5507769 Marin et al. Apr 1996 A
5507771 Gianturco Apr 1996 A
5522880 Barone et al. Jun 1996 A
5522881 Lentz Jun 1996 A
5522883 Slater et al. Jun 1996 A
5523092 Slater et al. Jun 1996 A
5545211 An et al. Aug 1996 A
5549635 Solar Aug 1996 A
5554118 Jang Sep 1996 A
5554181 Das Sep 1996 A
5562697 Christiansen Oct 1996 A
5562724 Vorwerk et al. Oct 1996 A
5562726 Chuter Oct 1996 A
5562728 Lazarus et al. Oct 1996 A
5571169 Plaia et al. Nov 1996 A
5571172 Chin Nov 1996 A
5571173 Parodi Nov 1996 A
5575816 Rudnick et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5578071 Parodi Nov 1996 A
5578072 Barone et al. Nov 1996 A
5591195 Taheri et al. Jan 1997 A
5591197 Orth et al. Jan 1997 A
5591198 Boyle et al. Jan 1997 A
5591226 Trerotola et al. Jan 1997 A
5591229 Parodi Jan 1997 A
5591230 Horn et al. Jan 1997 A
5593417 Rhodes Jan 1997 A
5604435 Foo et al. Feb 1997 A
5607445 Summers Mar 1997 A
5609625 Piplani et al. Mar 1997 A
5609627 Goicoechea et al. Mar 1997 A
5609628 Keranen Mar 1997 A
5628783 Quiachon et al. May 1997 A
5628786 Banas et al. May 1997 A
5628788 Pinchuk May 1997 A
5630829 Lauterjung May 1997 A
5630830 Verbeek May 1997 A
5632763 Glastra May 1997 A
5632772 Alcime et al. May 1997 A
5639278 Dereume et al. Jun 1997 A
5641373 Shannon et al. Jun 1997 A
5643171 Bradshaw et al. Jul 1997 A
5643278 Wijay Jul 1997 A
5643339 Kavteladze et al. Jul 1997 A
5647857 Anderson et al. Jul 1997 A
5649952 Lam Jul 1997 A
5651174 Schwartz et al. Jul 1997 A
5653727 Wiktor Aug 1997 A
5653743 Martin Aug 1997 A
5653746 Schmitt Aug 1997 A
5653747 Dereume Aug 1997 A
5662580 Bradshaw et al. Sep 1997 A
5662614 Edoga Sep 1997 A
5662675 Polanskyj Stockert et al. Sep 1997 A
5662700 Lazarus Sep 1997 A
5662701 Plaia et al. Sep 1997 A
5662702 Keranen Sep 1997 A
5662703 Yurek et al. Sep 1997 A
5665115 Cragg Sep 1997 A
5665117 Rhodes Sep 1997 A
5666968 Imran et al. Sep 1997 A
5669880 Solar Sep 1997 A
5669924 Shaknovich Sep 1997 A
5669934 Sawyer Sep 1997 A
5674241 Bley et al. Oct 1997 A
5674276 Andersen et al. Oct 1997 A
5676685 Razaivi Oct 1997 A
5676696 Marcade Oct 1997 A
5676697 McDonald Oct 1997 A
5679400 Tuch Oct 1997 A
5681345 Tuteneuer Oct 1997 A
5681346 Orth et al. Oct 1997 A
5683448 Cragg Nov 1997 A
5683449 Marcade Nov 1997 A
5683450 Goicoechea et al. Nov 1997 A
5683451 Lenker et al. Nov 1997 A
5683452 Barone et al. Nov 1997 A
5683453 Palmaz Nov 1997 A
5690642 Osborne et al. Nov 1997 A
5690643 Wijay Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5690671 McGurk et al. Nov 1997 A
5693066 Rupp et al. Dec 1997 A
5693084 Chuter Dec 1997 A
5693086 Goicoechea et al. Dec 1997 A
5693087 Parodi Dec 1997 A
5693088 Lazarus Dec 1997 A
5695516 Fischell et al. Dec 1997 A
5695517 Marin et al. Dec 1997 A
5697948 Marin et al. Dec 1997 A
5697971 Fischell et al. Dec 1997 A
5709703 Lukic et al. Jan 1998 A
5713917 Leonhardt Feb 1998 A
5716365 Goicoechea et al. Feb 1998 A
5716393 Lindenberg et al. Feb 1998 A
5718724 Goicoechea et al. Feb 1998 A
5718973 Lewis et al. Feb 1998 A
5720735 Dorros Feb 1998 A
5720776 Chuter et al. Feb 1998 A
5723004 Dereume et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5746776 Smith et al. May 1998 A
5749880 Banas et al. May 1998 A
5755735 Richter et al. May 1998 A
5755770 Ravenscroft May 1998 A
5755771 Penn et al. May 1998 A
5755777 Chuter May 1998 A
5765682 Bley et al. Jun 1998 A
5766203 Imran et al. Jun 1998 A
5769885 Quiachon et al. Jun 1998 A
5769887 Brown et al. Jun 1998 A
5782855 Lau et al. Jul 1998 A
5782909 Quiachon et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800508 Goicoechea et al. Sep 1998 A
5800526 Anderson et al. Sep 1998 A
5810836 Hussein et al. Sep 1998 A
5817100 Igaki Oct 1998 A
5823198 Jones et al. Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824039 Piplani et al. Oct 1998 A
5824040 Cox et al. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5843160 Rhodes Dec 1998 A
5843162 Inoue Dec 1998 A
5843164 Frantzen et al. Dec 1998 A
5843167 Dwyer et al. Dec 1998 A
5851228 Pinheiro Dec 1998 A
5855599 Wan Jan 1999 A
5855600 Alt Jan 1999 A
5860998 Robinson et al. Jan 1999 A
5867432 Toda Feb 1999 A
5868783 Tower Feb 1999 A
5871536 Lazarus Feb 1999 A
5873906 Lau et al. Feb 1999 A
5879321 Hill Mar 1999 A
5879366 Shaw et al. Mar 1999 A
5891193 Robinson et al. Apr 1999 A
5893868 Hanson et al. Apr 1999 A
5893887 Jayaraman Apr 1999 A
5902334 Dwyer et al. May 1999 A
5906640 Penn et al. May 1999 A
5906641 Thompson et al. May 1999 A
5916263 Goicoceha et al. Jun 1999 A
5919225 Lau et al. Jul 1999 A
5925075 Myers et al. Jul 1999 A
5928248 Acker Jul 1999 A
5928279 Shannon et al. Jul 1999 A
5935161 Robinson et al. Aug 1999 A
5938696 Goicoechea et al. Aug 1999 A
5948017 Taheri Sep 1999 A
5948018 Dereume et al. Sep 1999 A
5957929 Brenneman Sep 1999 A
5957973 Quiachon et al. Sep 1999 A
5961546 Robinson et al. Oct 1999 A
5961548 Shmulewitz Oct 1999 A
5980514 Kupiecki et al. Nov 1999 A
5984929 Bashiri et al. Nov 1999 A
5984955 Wisselink Nov 1999 A
5989242 Saadat et al. Nov 1999 A
5993489 Lewis et al. Nov 1999 A
6001125 Golds et al. Dec 1999 A
6004347 McNamara et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6017363 Hojeibane Jan 2000 A
6027508 Ren et al. Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6027779 Campbell et al. Feb 2000 A
6027811 Campbell et al. Feb 2000 A
6030415 Chuter Feb 2000 A
6033434 Borghi Mar 2000 A
6039749 Marin et al. Mar 2000 A
6039755 Edwin et al. Mar 2000 A
6039758 Quiachon et al. Mar 2000 A
6045557 White et al. Apr 2000 A
6051020 Goicoechea et al. Apr 2000 A
6053940 Wijay Apr 2000 A
6056722 Jayaraman May 2000 A
6059813 Vrba et al. May 2000 A
6059824 Taheri May 2000 A
6063092 Shin May 2000 A
6063113 Kavteladze et al. May 2000 A
6068654 Berg et al. May 2000 A
6070589 Keith et al. Jun 2000 A
6074398 Leschinsky Jun 2000 A
6077296 Shokoohi et al. Jun 2000 A
6077297 Robinson et al. Jun 2000 A
6086611 Duffy et al. Jul 2000 A
6090128 Douglas Jul 2000 A
6090135 Plaia et al. Jul 2000 A
6093194 Mikus et al. Jul 2000 A
6093203 Uflacker Jul 2000 A
6096027 Layne Aug 2000 A
6106548 Reubin et al. Aug 2000 A
6117167 Goicoechea et al. Sep 2000 A
6123722 Fogarty et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6126685 Lenker et al. Oct 2000 A
6129756 Kugler et al. Oct 2000 A
6136006 Johnson et al. Oct 2000 A
6143002 Vietmeier Nov 2000 A
6143016 Bleam et al. Nov 2000 A
6146389 Geitz Nov 2000 A
6146415 Fitz Nov 2000 A
6149681 Houser et al. Nov 2000 A
6152944 Holman et al. Nov 2000 A
6156063 Douglas Dec 2000 A
6162237 Chan Dec 2000 A
6165195 Wilson et al. Dec 2000 A
6165214 Lazarus Dec 2000 A
6168610 Marin et al. Jan 2001 B1
6171281 Zhang Jan 2001 B1
6183481 Lee et al. Feb 2001 B1
6183509 Dibie Feb 2001 B1
6187015 Brenneman Feb 2001 B1
6187033 Schmitt et al. Feb 2001 B1
6187036 Shaolian et al. Feb 2001 B1
6192944 Greenhalgh Feb 2001 B1
6193726 Vanney Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6197049 Shaolian et al. Mar 2001 B1
6203735 Edwin et al. Mar 2001 B1
6210429 Vardi et al. Apr 2001 B1
6221090 Wilson Apr 2001 B1
6221098 Wilson Apr 2001 B1
6221102 Baker et al. Apr 2001 B1
6224609 Ressemann et al. May 2001 B1
6224627 Armstrong et al. May 2001 B1
6231563 White et al. May 2001 B1
6235051 Murphy May 2001 B1
6254609 Vrba et al. Jul 2001 B1
6254628 Wallace et al. Jul 2001 B1
6261316 Shaolian et al. Jul 2001 B1
6264682 Wilson et al. Jul 2001 B1
6273909 Kugler et al. Aug 2001 B1
6280465 Cryer Aug 2001 B1
6280466 Kugler et al. Aug 2001 B1
6280467 Leonhardt Aug 2001 B1
6283991 Cox et al. Sep 2001 B1
6287329 Duering et al. Sep 2001 B1
6296622 Kurz et al. Oct 2001 B1
6312406 Jayaraman Nov 2001 B1
6325826 Vardi et al. Dec 2001 B1
6331184 Abrams Dec 2001 B1
6331190 Shokoohi et al. Dec 2001 B1
6334867 Anson Jan 2002 B1
6344056 Dehdashtian Feb 2002 B1
6346118 Baker et al. Feb 2002 B1
6348066 Pinchuk et al. Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6352553 Van der Burg et al. Mar 2002 B1
6352554 De Paulis Mar 2002 B2
6352561 Leopold et al. Mar 2002 B1
6355060 Lenker et al. Mar 2002 B1
6361544 Wilson et al. Mar 2002 B1
6361555 Wilson Mar 2002 B1
6361557 Gittings et al. Mar 2002 B1
6361559 Houser et al. Mar 2002 B1
6361637 Martin et al. Mar 2002 B2
6383213 Wilson et al. May 2002 B2
6387120 Wilson et al. May 2002 B2
6395017 Dwyer et al. May 2002 B1
6395018 Castaneda May 2002 B1
6395019 Chobotov May 2002 B2
6398807 Chouinard et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6409757 Trout, III et al. Jun 2002 B1
6416474 Penner et al. Jul 2002 B1
6416542 Marcade et al. Jul 2002 B1
6425765 Irwin, III Jul 2002 B1
6428565 Wisselink Aug 2002 B1
6428567 Wilson et al. Aug 2002 B2
6432131 Ravenscroft Aug 2002 B1
6432134 Anson et al. Aug 2002 B1
6436135 Goldfarb Aug 2002 B1
6440161 Madrid et al. Aug 2002 B1
6447540 Fontaine et al. Sep 2002 B1
6458152 Khosravi et al. Oct 2002 B1
6464721 Marcade et al. Oct 2002 B1
6432130 Hanson Nov 2002 B1
6475166 Escano Nov 2002 B1
6475170 Doron et al. Nov 2002 B1
6482211 Choi Nov 2002 B1
6485513 Fan Nov 2002 B1
6491719 Fogrty et al. Dec 2002 B1
6500182 Foster Dec 2002 B2
6500202 Shaolian et al. Dec 2002 B1
6508833 Pavcnick et al. Jan 2003 B2
6508835 Shaolian et al. Jan 2003 B1
6508836 Wilson et al. Jan 2003 B2
6511325 Lalka et al. Jan 2003 B1
6514281 Blaeser et al. Feb 2003 B1
6514282 Inoue Feb 2003 B1
6517572 Kugler et al. Feb 2003 B2
6517573 Pollock et al. Feb 2003 B1
6520988 Colombo et al. Feb 2003 B1
6524335 Hartley et al. Feb 2003 B1
6524336 Papazolgou et al. Feb 2003 B1
6533811 Ryan et al. Mar 2003 B1
6544278 Vrba et al. Apr 2003 B1
6551350 Thornton et al. Apr 2003 B1
6558396 Inoue May 2003 B1
6562063 Euteneurer et al. May 2003 B1
6565596 White et al. May 2003 B1
6565597 Fearnot et al. May 2003 B1
RE38146 Palmaz et al. Jun 2003 E
6572645 Leonhardt Jun 2003 B2
6576005 Geitz Jun 2003 B1
6576009 Ryan et al. Jun 2003 B2
6579308 Jansen et al. Jun 2003 B1
6579312 Wilson et al. Jun 2003 B2
6582394 Reiss et al. Jun 2003 B1
6582460 Cryer Jun 2003 B1
6585758 Chouinard et al. Jul 2003 B1
6592548 Jayaraman Jul 2003 B2
6592614 Lenker et al. Jul 2003 B2
6592615 Marcade et al. Jul 2003 B1
6599315 Wilson Jul 2003 B2
6607552 Hanson Aug 2003 B1
6613073 White et al. Sep 2003 B1
6616675 Evard et al. Sep 2003 B1
6645242 Quinn Nov 2003 B1
6652567 Deaton Nov 2003 B1
6652579 Cox et al. Nov 2003 B1
6656213 Solem Dec 2003 B2
6660033 Marcade et al. Dec 2003 B1
6663665 Shaolian et al. Dec 2003 B2
6669718 Besselink Dec 2003 B2
6692483 Vardi et al. Feb 2004 B2
6695875 Stelter et al. Feb 2004 B2
6706062 Vardi et al. Mar 2004 B2
6723116 Taheri Apr 2004 B2
6702843 Brown et al. May 2004 B1
6733523 Shaolian et al. May 2004 B2
6740101 Houser et al. May 2004 B2
6761733 Chobotov et al. Jul 2004 B2
6767359 Weadock Jul 2004 B2
6773457 Ivancev et al. Aug 2004 B2
6790224 Gerberding Sep 2004 B2
6793671 Wall Sep 2004 B2
6800065 Duane et al. Oct 2004 B2
6802859 Pazienza et al. Oct 2004 B1
6811566 Penn et al. Nov 2004 B1
6814752 Chuter Nov 2004 B1
6818014 Brown et al. Nov 2004 B2
6821292 Pazienza et al. Nov 2004 B2
6827706 Parodi Dec 2004 B2
6827726 Parodi Dec 2004 B2
6833003 Jones et al. Dec 2004 B2
6835203 Vardi et al. Dec 2004 B1
6840950 Standford et al. Jan 2005 B2
6858038 Heuser Feb 2005 B2
6875229 Wilson et al. Apr 2005 B2
6887249 Houser et al. May 2005 B1
6887251 Suval May 2005 B1
6889026 Schlageter et al. May 2005 B2
6896699 Wilson et al. May 2005 B2
6899727 Armstrong et al. May 2005 B2
6899728 Phillips et al. May 2005 B1
6905505 Nash et al. Jun 2005 B2
6908477 McGuckin Jun 2005 B2
6918925 Tehrani Jul 2005 B2
6923829 Boyle et al. Aug 2005 B2
6929661 Bolduc et al. Aug 2005 B2
6932837 Amplatz et al. Aug 2005 B2
6939368 Simso Sep 2005 B2
6939371 Kugler et al. Sep 2005 B2
6939377 Jayaraman et al. Sep 2005 B2
6942691 Chuter Sep 2005 B1
6942692 Landau et al. Sep 2005 B2
6942693 Chouinard et al. Sep 2005 B2
6948017 Carpenter et al. Sep 2005 B2
6953475 Shaolian et al. Oct 2005 B2
6955679 Hendricksen et al. Oct 2005 B1
6955688 Wilson et al. Oct 2005 B2
6960217 Bolduc Nov 2005 B2
6962602 Vardi Nov 2005 B2
6974471 Van Schie et al. Dec 2005 B2
6981982 Armstrong et al. Jan 2006 B2
6984244 Perez et al. Jan 2006 B2
6989024 Hebert et al. Jan 2006 B2
6989026 Richter et al. Jan 2006 B2
6994721 Israel Feb 2006 B2
6994722 DiCarlo Feb 2006 B2
7004926 Navia et al. Feb 2006 B2
7004964 Thompson et al. Feb 2006 B2
7004967 Chouinard et al. Feb 2006 B2
7014653 Ouriel et al. Mar 2006 B2
7025779 Elliott Apr 2006 B2
7029494 Soun et al. Apr 2006 B2
7029496 Rakos et al. Apr 2006 B2
7074235 Roy Jul 2006 B1
7074236 Rabkin et al. Jul 2006 B2
7105015 Goshgarian Sep 2006 B2
7105017 Kerr Sep 2006 B2
7105020 Greenberg et al. Sep 2006 B2
7118593 Davidson et al. Oct 2006 B2
7122051 Dallara et al. Oct 2006 B1
7122052 Greenhalgh Oct 2006 B2
7125464 Chobotov et al. Oct 2006 B2
7131991 Zarins et al. Nov 2006 B2
7144422 Rao Dec 2006 B1
7160318 Greenberg et al. Jan 2007 B2
7162302 Wang et al. Jan 2007 B2
7163715 Kramer Jan 2007 B1
7175651 Kerr Feb 2007 B2
7175652 Cook et al. Feb 2007 B2
7175657 Khan et al. Feb 2007 B2
7189256 Smith Mar 2007 B2
7189257 Schmitt et al. Mar 2007 B2
7195648 Jones et al. Mar 2007 B2
7201770 Johnson et al. Apr 2007 B2
7220274 Quinn May 2007 B1
7220275 Davidson et al. May 2007 B2
7229472 DePalma et al. Jun 2007 B2
7232449 Sharkawy et al. Jun 2007 B2
7235095 Haverkost et al. Jun 2007 B2
7237552 Khera et al. Jul 2007 B2
7241300 Sharkawy et al. Jul 2007 B2
7244444 Bates Jul 2007 B2
7261733 Brown et al. Aug 2007 B1
7264631 DeCarlo Sep 2007 B2
7264632 Wright et al. Sep 2007 B2
7267685 Butaric et al. Sep 2007 B2
7270675 Chun et al. Sep 2007 B2
7285130 Austin Oct 2007 B2
7294145 Ward Nov 2007 B2
7300460 Levine et al. Nov 2007 B2
7306623 Watson Dec 2007 B2
7309351 Escamilla et al. Dec 2007 B2
7314481 Karpiel Jan 2008 B2
7314483 Landau et al. Jan 2008 B2
7320703 DiMatteo et al. Jan 2008 B2
7341598 Davidson et al. Mar 2008 B2
7367985 Mazzocchi et al. May 2008 B2
7367986 Mazzocchi et al. May 2008 B2
7371250 Mazzocchi et al. May 2008 B2
7402168 Acosta et al. Jul 2008 B2
7402171 Osborne et al. Jul 2008 B2
7413573 Hartley et al. Aug 2008 B2
7425219 Quadri et al. Sep 2008 B2
7435253 Hartley et al. Oct 2008 B1
7438721 Doig et al. Oct 2008 B2
7491230 Holman et al. Feb 2009 B2
7491232 Bolduc et al. Feb 2009 B2
7520890 Phillips Apr 2009 B2
7520895 Douglas et al. Apr 2009 B2
7527636 Dunfee et al. May 2009 B2
7537606 Hartley May 2009 B2
7553324 Andreas et al. Jun 2009 B2
7572289 Sisken et al. Aug 2009 B2
7575590 Watson Aug 2009 B2
7578841 Yadin et al. Aug 2009 B2
7582111 Krolik et al. Sep 2009 B2
7591832 Eversull et al. Sep 2009 B2
7591843 Escano et al. Sep 2009 B1
7611529 Greenberg et al. Nov 2009 B2
7615072 Rust et al. Nov 2009 B2
7618398 Holman et al. Nov 2009 B2
7632299 Weber Dec 2009 B2
7635383 Gumm Dec 2009 B2
7637932 Bolduc et al. Dec 2009 B2
7641684 Hilaire et al. Jan 2010 B2
7645298 Hartley et al. Jan 2010 B2
7651519 Dittman Jan 2010 B2
7670369 Shaeffer et al. Mar 2010 B2
7674284 Melsheimer Mar 2010 B2
7678141 Greenan et al. Mar 2010 B2
7691135 Shaolian et al. Apr 2010 B2
7695508 Van Der Leest et al. Apr 2010 B2
7699885 Leonhardt et al. Apr 2010 B2
7708771 Chuter et al. May 2010 B2
7708773 Pinchuk et al. May 2010 B2
7722657 Hartley May 2010 B2
7753951 Shaked et al. Jul 2010 B2
7758633 Nazzaro Jul 2010 B2
7766961 Patel et al. Aug 2010 B2
7771465 Zukowski Aug 2010 B2
7785340 Heidner et al. Aug 2010 B2
7785361 Nikolchev et al. Aug 2010 B2
7806917 Xiao Oct 2010 B2
7815601 Jordan et al. Oct 2010 B2
7815661 Mirizzi et al. Oct 2010 B2
7828837 Khoury Nov 2010 B2
7833259 Boatman Nov 2010 B2
7867270 Hartley Jan 2011 B2
7879081 DeMatteo et al. Feb 2011 B2
7892275 Hartley et al. Feb 2011 B2
7909873 Tan-Malecki et al. Mar 2011 B2
7914572 Hartley et al. Mar 2011 B2
8034100 Shaolian et al. Oct 2011 B2
8118856 Schreck et al. Feb 2012 B2
8152830 Gumm Apr 2012 B2
8216295 Bemjamin et al. Jul 2012 B2
8221494 Schreck et al. Jul 2012 B2
8236040 Mayberry et al. Aug 2012 B2
8343204 Osborne Jan 2013 B2
8357192 Mayberry et al. Jan 2013 B2
8491646 Schreck Jul 2013 B2
8523931 Mayberry et al. Sep 2013 B2
8672989 Schreck et al. Mar 2014 B2
8764812 Mayberry et al. Jul 2014 B2
8808350 Schreck et al. Aug 2014 B2
8828074 Xiao et al. Sep 2014 B2
8845708 Hartley et al. Sep 2014 B2
8945202 Mayberry et al. Feb 2015 B2
9149381 Schreck et al. Oct 2015 B2
20010003161 Vardi et al. Jun 2001 A1
20010014823 Ressemann Aug 2001 A1
20010016767 Wilson et al. Aug 2001 A1
20010027338 Greenberg Oct 2001 A1
20010037142 Stelter et al. Nov 2001 A1
20010039445 Hall et al. Nov 2001 A1
20020042650 Vardi et al. Apr 2002 A1
20020049412 Madrid et al. Apr 2002 A1
20020052644 Shaolian et al. May 2002 A1
20020052648 McGuckin et al. May 2002 A1
20020058986 Landau et al. May 2002 A1
20020123786 Gittings et al. Sep 2002 A1
20020138088 Nash et al. Sep 2002 A1
20020143383 Parodi Oct 2002 A1
20020147491 Khan et al. Oct 2002 A1
20020156516 Vardi Oct 2002 A1
20020156518 Tehrani Oct 2002 A1
20020173835 Bourang et al. Nov 2002 A1
20020193872 Trout et al. Dec 2002 A1
20020198585 Wisselink Dec 2002 A1
20030004560 Chobotov et al. Jan 2003 A1
20030028233 Vardi et al. Feb 2003 A1
20030083678 Herweck et al. May 2003 A1
20030097169 Brucker et al. May 2003 A1
20030167083 Lashinski et al. Sep 2003 A1
20030176910 Vrba et al. Sep 2003 A1
20030191491 Duane et al. Oct 2003 A1
20030236565 DiMatteo et al. Dec 2003 A1
20030236566 Heuser Dec 2003 A1
20040049204 Harari et al. Mar 2004 A1
20040049257 Kaspersen et al. Mar 2004 A1
20040073288 Kerr Apr 2004 A1
20040093058 Cottone et al. May 2004 A1
20040098084 Hartley et al. May 2004 A1
20040098096 Eton May 2004 A1
20040106972 Deaton Jun 2004 A1
20040127975 Levine et al. Jul 2004 A1
20040143312 Samson et al. Jul 2004 A1
20040167618 Shaolian et al. Aug 2004 A1
20040176832 Hartley et al. Sep 2004 A1
20040193254 Greenberg et al. Sep 2004 A1
20040215327 Doig et al. Oct 2004 A1
20040230287 Hartley et al. Nov 2004 A1
20040236403 Leonhardt et al. Nov 2004 A1
20050015135 Shanley Jan 2005 A1
20050033403 Ward et al. Feb 2005 A1
20050033405 Solovay Feb 2005 A1
20050038494 Eidenschink Feb 2005 A1
20050049672 Murphy Mar 2005 A1
20050058327 Pieper Mar 2005 A1
20050059923 Gamboa Mar 2005 A1
20050059994 Walak et al. Mar 2005 A1
20050060025 Mackiewicz et al. Mar 2005 A1
20050060026 Gamboa Mar 2005 A1
20050080476 Gunderson et al. Apr 2005 A1
20050085845 Hilaire et al. Apr 2005 A1
20050085891 Goto et al. Apr 2005 A1
20050102018 Carpenter et al. May 2005 A1
20050113693 Smith et al. May 2005 A1
20050113853 Noriega et al. May 2005 A1
20050113905 Greenberg et al. May 2005 A1
20050119719 Wallace et al. Jun 2005 A1
20050119731 Brucker et al. Jun 2005 A1
20050121120 Van Dijk et al. Jun 2005 A1
20050131517 Hartley et al. Jun 2005 A1
20050131518 Hartley et al. Jun 2005 A1
20050131519 Hartley Jun 2005 A1
20050131526 Wong Jun 2005 A1
20050149166 Schaeffer et al. Jul 2005 A1
20050154444 Quadri Jul 2005 A1
20050159803 Lad et al. Jul 2005 A1
20050165470 Weber Jul 2005 A1
20050165480 Jordan et al. Jul 2005 A1
20050171597 Boatman et al. Aug 2005 A1
20050171598 Schaeffer Aug 2005 A1
20050177221 Mustapha Aug 2005 A1
20050215327 Weisel et al. Sep 2005 A1
20050216043 Blatter et al. Sep 2005 A1
20050222668 Schaeffer et al. Oct 2005 A1
20050228480 Douglas et al. Oct 2005 A1
20050240153 Opie Oct 2005 A1
20050240258 Bolduc et al. Oct 2005 A1
20050240260 Bolduc Oct 2005 A1
20050273150 Howel et al. Dec 2005 A1
20050288772 Douglas et al. Dec 2005 A1
20060020320 Shaolian et al. Jan 2006 A1
20060036315 Yadin et al. Feb 2006 A1
20060058864 Schaeffer et al. Mar 2006 A1
20060074475 Gumm Apr 2006 A1
20060089704 Douglas Apr 2006 A1
20060142704 Lentz Jun 2006 A1
20060142838 Molaei et al. Jun 2006 A1
20060149350 Patel et al. Jul 2006 A1
20060155358 LaDuca et al. Jul 2006 A1
20060155363 LaDuca et al. Jul 2006 A1
20060155366 LaDuca et al. Jul 2006 A1
20060161244 Sequin Jul 2006 A1
20060173525 Behl et al. Aug 2006 A1
20060178726 Myles Aug 2006 A1
20060217794 Ruiz et al. Sep 2006 A1
20060224232 Chobotov Oct 2006 A1
20060229669 Mirizzi et al. Oct 2006 A1
20060229699 Tehrani et al. Oct 2006 A1
20060229700 Acosta et al. Oct 2006 A1
20060229707 Khoury Oct 2006 A1
20060233990 Humphrey et al. Oct 2006 A1
20060233991 Humphrey et al. Oct 2006 A1
20060247760 Ganesan et al. Nov 2006 A1
20060247761 Greenberg et al. Nov 2006 A1
20060259063 Bates et al. Nov 2006 A1
20060271163 Shokoohi Nov 2006 A1
20060271164 Shaolian et al. Nov 2006 A1
20070010867 Carter et al. Jan 2007 A1
20070016280 Yacoby et al. Jan 2007 A1
20070021828 Krolik et al. Jan 2007 A1
20070027522 Chang et al. Feb 2007 A1
20070027526 Demetriades et al. Feb 2007 A1
20070043425 Hartley et al. Feb 2007 A1
20070050016 Gregorich et al. Mar 2007 A1
20070055350 Erickson Mar 2007 A1
20070055360 Hanson et al. Mar 2007 A1
20070055362 Brown Mar 2007 A1
20070067019 Miller et al. Mar 2007 A1
20070067023 Kveen et al. Mar 2007 A1
20070073376 Krolik et al. Mar 2007 A1
20070073388 Krolik et al. Mar 2007 A1
20070088424 Greenberg et al. Apr 2007 A1
20070112420 LaDuca May 2007 A1
20070118208 Kerr May 2007 A1
20070123805 Shireman et al. May 2007 A1
20070142896 Anderson et al. Jun 2007 A1
20070150051 Arnault De La Menardiere et al. Jun 2007 A1
20070167955 Arnault De La Menardiere et al. Jul 2007 A1
20070168019 Amplatz et al. Jul 2007 A1
20070173921 Wholey et al. Jul 2007 A1
20070179592 Schaeffer Aug 2007 A1
20070198076 Hebert et al. Aug 2007 A1
20070203571 Kaplan et al. Aug 2007 A1
20070213804 Schaeffer et al. Sep 2007 A1
20070219620 Eells et al. Sep 2007 A1
20070219621 Hartley et al. Sep 2007 A1
20070225796 Yadin et al. Sep 2007 A1
20070225797 Krivoruhko Sep 2007 A1
20070225798 Gregorich Sep 2007 A1
20070233220 Greenan Oct 2007 A1
20070244540 Pryor Oct 2007 A1
20070244542 Greenan et al. Oct 2007 A1
20070244547 Greenan Oct 2007 A1
20070248640 Karabey et al. Oct 2007 A1
20070250084 Sharkway et al. Oct 2007 A1
20070260302 Igaki Nov 2007 A1
20070260304 Gregorich et al. Nov 2007 A1
20070149166 Schaeffer et al. Dec 2007 A1
20070293940 Schaeffer et al. Dec 2007 A1
20070299494 Zukowski Dec 2007 A1
20070299495 Zukowski et al. Dec 2007 A1
20070299497 Shaolian et al. Dec 2007 A1
20070299499 Hartley Dec 2007 A1
20070299501 Hebert et al. Dec 2007 A1
20080009932 Ta et al. Jan 2008 A1
20080009933 Ta et al. Jan 2008 A1
20080009937 Kipperman Jan 2008 A1
20080015681 Wilson Jan 2008 A1
20080033525 Shaked et al. Feb 2008 A1
20080046066 Jenson et al. Feb 2008 A1
20080058918 Watson Mar 2008 A1
20080065197 Meyer et al. Mar 2008 A1
20080071343 Mayberry et al. Mar 2008 A1
20080086191 Valencia Apr 2008 A1
20080109065 Bowe May 2008 A1
20080114444 Yu May 2008 A1
20080114446 Hartley May 2008 A1
20080133000 Molony Jun 2008 A1
20080167704 Wright et al. Jul 2008 A1
20080172119 Yamasaki et al. Jul 2008 A1
20080172122 Mayberry et al. Jul 2008 A1
20080188921 Yamasaki et al. Aug 2008 A1
20080208319 Rabkin et al. Aug 2008 A1
20080255652 Thomas et al. Oct 2008 A1
20080262595 Chu et al. Oct 2008 A1
20080262596 Xiao Oct 2008 A1
20080269866 Hamer et al. Oct 2008 A1
20080269867 Johnson Oct 2008 A1
20080275542 LaDuca Nov 2008 A1
20080281399 Hartley Nov 2008 A1
20080288044 Osborne Nov 2008 A1
20080294237 Chu Nov 2008 A1
20090005847 Adams Jan 2009 A1
20090012602 Quadri Jan 2009 A1
20090043373 Arnault de la Menardiere et al. Feb 2009 A1
20090043377 Greenberg et al. Feb 2009 A1
20090048663 Greenberg Feb 2009 A1
20090069880 Vonderwalde et al. Mar 2009 A1
20090088791 Drasler et al. Apr 2009 A1
20090099649 Chobotov et al. Apr 2009 A1
20090109065 Pinheiro Apr 2009 A1
20090132024 Berkhoff May 2009 A1
20090155337 Schreck et al. Jun 2009 A1
20090164001 Biggs et al. Jun 2009 A1
20090240316 Bruszewski Sep 2009 A1
20090254170 Hartley et al. Oct 2009 A1
20090259290 Bruszewski et al. Oct 2009 A1
20090259296 McIff et al. Oct 2009 A1
20090259298 Mayberry et al. Oct 2009 A1
20090264985 Bruszewski Oct 2009 A1
20090287145 Cragg et al. Nov 2009 A1
20100063575 Shalev et al. Mar 2010 A1
20100063576 Schaeffer et al. Mar 2010 A1
20100094390 Goldmann et al. Apr 2010 A1
20100179636 Mayberry et al. Jul 2010 A1
20100179638 Shaolian et al. Jul 2010 A1
20100261662 Schreck et al. Oct 2010 A1
20110054586 Mayberry et al. Mar 2011 A1
20110054587 Mayberry et al. Mar 2011 A1
20110224772 Mayberry et al. Sep 2011 A1
20110288627 Hartley et al. Nov 2011 A1
20120109279 Mayberry May 2012 A1
20140249615 Schreck Sep 2014 A1
20140350658 Benary et al. Nov 2014 A1
20150173932 Mayberry Jun 2015 A1
20150366688 Schreck Dec 2015 A1
Foreign Referenced Citations (91)
Number Date Country
2220141 Nov 1996 CA
2133530 Jan 1999 CA
295 21 548 Feb 1995 DE
295 21 776 Feb 1995 DE
100 17 147 Oct 2001 DE
0 282 175 Sep 1988 EP
0 323 176 Jul 1989 EP
0 177 330 Jun 1991 EP
0 458 568 Nov 1991 EP
0 596 145 May 1994 EP
0 621 015 Oct 1994 EP
0 659 389 Jun 1995 EP
0 688 545 Dec 1995 EP
0 689 806 Jan 1996 EP
0 712 614 May 1996 EP
0 732 088 Sep 1996 EP
0 732 089 Sep 1996 EP
0 732 089 Sep 1996 EP
0 740 928 Nov 1996 EP
0 740 928 Nov 1996 EP
0 747 020 Dec 1996 EP
0 732 089 Feb 1997 EP
0 775 470 May 1997 EP
0 782 841 Jul 1997 EP
0 783 873 Jul 1997 EP
0 783 874 Jul 1997 EP
0 880 938 Dec 1998 EP
0 880 948 Dec 1998 EP
0 904 745 Mar 1999 EP
0 974 314 Jan 2000 EP
0 732 088 Apr 2000 EP
1 433 438 Jun 2004 EP
1 470 797 Oct 2004 EP
0 935 374 Jan 2005 EP
1 935 374 Jun 2008 EP
2 429 452 Mar 2012 EP
2 635 241 Sep 2013 EP
1 038 606 Jul 1998 ES
04-25755 Jan 1992 JP
08-336597 Dec 1996 JP
9-511160 Nov 1997 JP
2000-500047 Jan 2000 JP
2007-236472 Sep 2007 JP
5629871 Oct 2014 JP
WO 9313825 Jul 1993 WO
WO 9424961 Nov 1994 WO
WO 9521592 Aug 1995 WO
WO 9634580 Nov 1996 WO
WO 9639999 Dec 1996 WO
WO 9641589 Dec 1996 WO
WO 9710757 Mar 1997 WO
WO 9710777 Mar 1997 WO
WO 9714375 Apr 1997 WO
WO 9719652 Jun 1997 WO
WO 9726936 Jul 1997 WO
WO 97033532 Sep 1997 WO
WO 97045072 Dec 1997 WO
WO 9802100 Jan 1998 WO
WO 9811846 Mar 1998 WO
WO 9827894 Jul 1998 WO
WO 9827895 Jul 1998 WO
WO 9853761 Dec 1998 WO
WO 9913808 Mar 1999 WO
WO 99029262 Jun 1999 WO
WO 9944536 Sep 1999 WO
WO 9947077 Sep 1999 WO
WO 9953865 Oct 1999 WO
WO 9958084 Nov 1999 WO
WO 0033769 Jun 2000 WO
WO 0053251 Sep 2000 WO
WO 0103762 Jan 2001 WO
WO 0126707 Apr 2001 WO
WO 01067993 Sep 2001 WO
WO 0239888 May 2002 WO
WO 03094796 Nov 2003 WO
WO 04047885 Jun 2004 WO
WO 04089249 Oct 2004 WO
WO 04105693 Dec 2004 WO
WO 05037076 Apr 2005 WO
WO 05037141 Apr 2005 WO
WO 06028925 Mar 2006 WO
WO 06036690 Apr 2006 WO
WO 06047708 May 2006 WO
WO 07027830 Mar 2007 WO
WO 08034106 Mar 2008 WO
WO 08083767 Jul 2008 WO
WO 08086084 Jul 2008 WO
WO 09000546 Dec 2008 WO
WO 09105699 Aug 2009 WO
WO 10127040 Nov 2010 WO
WO 12061526 May 2012 WO
Non-Patent Literature Citations (5)
Entry
US 6,413,270 B1, 07/2002, Thornton et al. (withdrawn)
Definition of mounted, Dictionary.com, retrieved Nov. 18, 2010 from http://dictionary.com/browse/mounted.
International Preliminary Report on Patentability and Written Opinion, dated Aug. 24, 2010, re PCT/US200934755 in 7 pages.
International Search Report and Written Opinion of the International Searching Authority, dated Apr. 13, 2009, re PCT/US200934755 in 12 pages.
Minion et al., “Technique of slow deployment of Gore Excluder endograft improves accuracy of placement”, J Vasc. Surg. 43:852-4, 2006.
Related Publications (1)
Number Date Country
20170266025 A1 Sep 2017 US
Provisional Applications (1)
Number Date Country
61030913 Feb 2008 US
Continuations (4)
Number Date Country
Parent 14840428 Aug 2015 US
Child 15610242 US
Parent 14172126 Feb 2014 US
Child 14840428 US
Parent 13546950 Jul 2012 US
Child 14172126 US
Parent 12390346 Feb 2009 US
Child 13546950 US